State Street Corporation has acquired a 5.2% stake in Syndax Pharmaceuticals, signaling increased interest in the pharmaceutical sector.
| Name | Syndax Pharmaceuticals Inc |
|---|---|
| CIK | 0001395937 |
| Tickers | SNDX |
| Exchanges | Nasdaq |
| Entity type | operating |
| Category | Large accelerated filer |
| SIC | 2834 Pharmaceutical Preparations |
| EIN | 320162505 |
| LEI | — |
| Fiscal year end | 1231 |
| State of incorporation | DE DE |
| Phone | 781-419-1400 |
| Website | — |
| Investor website | — |
| Owner org | 03 Life Sciences |
| Flags | — |
| Description | — |
| Insider transactions (issuer) | 1 |
| Insider transactions (owner) | 0 |
EDGAR has no company-logo API. Website field is shown when the filer provided one.
State Street Corporation has acquired a 5.2% stake in Syndax Pharmaceuticals, signaling increased interest in the pharmaceutical sector.
Syndax Pharmaceuticals files Q3 2026 report, detailing financial metrics and project updates in the pharmaceutical preparations sector.
Syndax Pharmaceuticals reveals CFO Keith Goldan's retirement and Aaron Ondrey's appointment as his successor, effective November 9, 2026.
Syndax Pharmaceuticals Inc. director Dennis Podlesak reports stock transactions, including acquisitions and sales, highlighting management activity.
Syndax Pharmaceuticals director Dennis G. Podlesak sells 8,000 shares in a recent SEC filing, reflecting ongoing activity in the pharmaceutical sector.
660 filing rows loaded from submissions recent.
| Filed | Form | Document | Items | Accession | File no. | Film | Act | Size | XBRL | iXBRL |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-12 | 4 | 4 | 0001193125-26-458304 | 5630 | ||||||
| 2026-11-12 | 3 | 3 | 0001193125-26-458245 | 3056 | ||||||
| 2026-11-10 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0000093751-26-000728 | 005-89449 | 261538359 | 34 | 8129 | |||
| 2026-11-02 | 10-Q | 10-Q | 0001193125-26-443625 | 001-37708 | 261512258 | 34 | 9229987 | 1 | 1 | |
| 2026-11-02 | 8-K | 8-K | 2.02,5.02,9.01 | 0001193125-26-443613 | 001-37708 | 261512219 | 34 | 7727732 | 1 | 1 |
| 2026-10-30 | 4 | 4 | 0001193125-26-442119 | 8643 | ||||||
| 2026-10-29 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-010480 | 001-37708 | 261502147 | 33 | 4783 | |||
| 2026-08-07 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0000093751-26-000542 | 005-89449 | 261252336 | 34 | 8255 | |||
| 2026-08-04 | 10-Q | 10-Q | 0001193125-26-332750 | 001-37708 | 261238463 | 34 | 9127423 | 1 | 1 | |
| 2026-08-04 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-332736 | 001-37708 | 261238399 | 34 | 8615371 | 1 | 1 |
| 2026-07-14 | 8-K | 8-K | 8.01,9.01 | 0001193125-26-302608 | 001-37708 | 261172588 | 34 | 37205865 | 1 | 1 |
| 2026-07-09 | 4 | 4 | 0001193125-26-299803 | 8642 | ||||||
| 2026-07-08 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-006967 | 001-37708 | 261162786 | 33 | 5552 | |||
| 2026-06-12 | 4 | 4 | 0001193125-26-269694 | 13881 | ||||||
| 2026-06-12 | 144 | xsl144X01/primary_doc.xml | 0001959173-26-004618 | 001-37708 | 261086744 | 33 | 5085 | |||
| 2026-06-11 | 144 | xsl144X01/primary_doc.xml | 0001959173-26-004566 | 001-37708 | 261083156 | 33 | 5518 | |||
| 2026-06-10 | 8-K | 8-K | 1.01,2.03,3.02,9.01 | 0001193125-26-266027 | 001-37708 | 261080530 | 34 | 1060964 | 1 | 1 |
| 2026-06-10 | 8-K | 8-K | 5.02,5.07,9.01 | 0001193125-26-265852 | 001-37708 | 261079830 | 34 | 769347 | 1 | 1 |
| 2026-06-04 | DEFA14A | DEFA14A | 0001193125-26-256557 | 001-37708 | 261063311 | 34 | 276830 | 1 | 1 | |
| 2026-06-04 | 8-K | 8-K | 1.01,2.03,3.02,8.01,9.01 | 0001193125-26-256458 | 001-37708 | 261063204 | 34 | 303236 | 1 | 1 |
| 2026-06-02 | 4 | 4 | 0001193125-26-253603 | 4783 | ||||||
| 2026-06-02 | 4 | 4 | 0001193125-26-253601 | 4818 | ||||||
| 2026-06-01 | 144 | xsl144X01/primary_doc.xml | 0001959173-26-004218 | 001-37708 | 261050340 | 33 | 4479 | |||
| 2026-06-01 | 144 | xsl144X01/primary_doc.xml | 0001959173-26-004216 | 001-37708 | 261050284 | 33 | 4559 | |||
| 2026-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000919574-26-003472 | 005-89449 | 26987911 | 34 | 12282 | |||
| 2026-04-30 | ARS | ARS | 0001193125-26-197892 | 001-37708 | 26927365 | 34 | 2422293 | |||
| 2026-04-30 | DEFA14A | DEFA14A | 0001193125-26-197877 | 001-37708 | 26927332 | 34 | 1565586 | 1 | 1 | |
| 2026-04-30 | DEF 14A | DEF 14A | 0001193125-26-197859 | 001-37708 | 26927293 | 34 | 7306385 | 1 | 1 | |
| 2026-04-30 | 10-Q | 10-Q | 0001193125-26-197154 | 001-37708 | 26924975 | 34 | 7068258 | 1 | 1 | |
| 2026-04-30 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-197124 | 001-37708 | 26924864 | 34 | 9840735 | 1 | 1 |
| 2026-04-30 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0002100119-26-001081 | 005-89449 | 26922961 | 34 | 7417 | |||
| 2026-03-27 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000102909-26-002306 | 005-89449 | 26804556 | 34 | 7182 | |||
| 2026-02-26 | S-8 | S-8 | 0001193125-26-076822 | 333-293792 | 26689041 | 33 | 303806 | 1 | 1 | |
| 2026-02-26 | 10-K | 10-K | 0001193125-26-076536 | 001-37708 | 26687785 | 34 | 16365412 | 1 | 1 | |
| 2026-02-26 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-076522 | 001-37708 | 26687661 | 34 | 8529824 | 1 | 1 |
| 2026-02-10 | 4 | 4 | 0001193125-26-043814 | 4681 | ||||||
| 2026-02-10 | 4 | 4 | 0001193125-26-043813 | 4645 | ||||||
| 2026-02-09 | 144 | xsl144X01/primary_doc.xml | 0001959173-26-000773 | 001-37708 | 26611344 | 33 | 5211 | |||
| 2026-02-09 | 144 | xsl144X01/primary_doc.xml | 0001959173-26-000771 | 001-37708 | 26611269 | 33 | 5101 | |||
| 2026-02-09 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0000093751-26-000090 | 005-89449 | 26609679 | 34 | 8050 | |||
| 2026-02-06 | 4 | 4 | 0001193125-26-041500 | 10657 | ||||||
| 2026-02-06 | 4 | 4 | 0001193125-26-041497 | 12251 | ||||||
| 2026-02-06 | 4 | 4 | 0001193125-26-041412 | 4757 | ||||||
| 2026-02-06 | 4 | 4 | 0001193125-26-041344 | 4759 | ||||||
| 2026-02-06 | 4 | 4 | 0001193125-26-041334 | 9035 | ||||||
| 2026-02-06 | 4 | 4 | 0001193125-26-041200 | 4819 | ||||||
| 2026-02-06 | 4 | 4 | 0001193125-26-041194 | 4748 | ||||||
| 2026-02-06 | 4 | 4 | 0001193125-26-041192 | 4763 | ||||||
| 2026-02-06 | 4 | 4 | 0001193125-26-041167 | 4741 | ||||||
| 2026-02-06 | 144 | xsl144X01/primary_doc.xml | 0001959173-26-000725 | 001-37708 | 26607410 | 33 | 4561 | |||
| 2026-02-06 | 144 | xsl144X01/primary_doc.xml | 0001959173-26-000723 | 001-37708 | 26607388 | 33 | 4470 | |||
| 2026-01-30 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000102909-26-000252 | 005-89449 | 26582583 | 34 | 7019 | |||
| 2026-01-12 | 8-K | 8-K | 2.02,7.01 | 0001193125-26-010486 | 001-37708 | 26527232 | 34 | 225500 | 1 | 1 |
| 2025-12-19 | 8-K | 8-K | 5.03 | 0001193125-25-326961 | 001-37708 | 251587955 | 34 | 440576 | 1 | 1 |
| 2025-12-01 | 4 | 4 | 0001193125-25-303941 | 4360 | ||||||
| 2025-11-03 | 10-Q | 10-Q | 0001193125-25-262521 | 001-37708 | 251444023 | 34 | 7984576 | 1 | 1 | |
| 2025-11-03 | 8-K | 8-K | 2.02,9.01 | 0001193125-25-262509 | 001-37708 | 251443976 | 34 | 8850334 | 1 | 1 |
| 2025-10-24 | 8-K | 8-K | 8.01,9.01 | 0001193125-25-250052 | 001-37708 | 251416638 | 34 | 248443 | 1 | 1 |
| 2025-09-08 | 4 | 4 | 0000950170-25-113659 | 8593 | ||||||
| 2025-09-08 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-006849 | 001-37708 | 251300327 | 33 | 5553 | |||
| 2025-08-18 | 4 | 4 | 0000950170-25-109815 | 20336 | ||||||
| 2025-08-18 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0000902664-25-003741 | 005-89449 | 251228534 | 34 | 16537 | |||
| 2025-08-18 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-005995 | 001-37708 | 251228393 | 33 | 6230 | |||
| 2025-08-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000902664-25-003706 | 005-89449 | 251221359 | 34 | 12146 | |||
| 2025-08-14 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-005839 | 001-37708 | 251219759 | 33 | 5019 | |||
| 2025-08-13 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000769993-25-000479 | 005-89449 | 251213282 | 34 | 16885 | |||
| 2025-08-07 | 4 | 4 | 0000950170-25-105258 | 4662 | ||||||
| 2025-08-04 | 10-Q | 10-Q | 0000950170-25-101985 | 001-37708 | 251180240 | 34 | 8381561 | 1 | 1 | |
| 2025-08-04 | 8-K | 8-K | 2.02,9.01 | 0000950170-25-101974 | 001-37708 | 251180127 | 34 | 7546354 | 1 | 1 |
| 2025-07-18 | 4 | 4 | 0000950170-25-096948 | 4633 | ||||||
| 2025-07-18 | 4 | 4 | 0000950170-25-096947 | 4669 | ||||||
| 2025-07-16 | 144 | xsl144X01/primary_doc.xml | 0001959173-25-004606 | 001-37708 | 251127270 | 33 | 4467 | |||
| 2025-07-16 | 144 | xsl144X01/primary_doc.xml | 0001959173-25-004605 | 001-37708 | 251127243 | 33 | 4554 | |||
| 2025-07-10 | 144 | xsl144X01/primary_doc.xml | 0001959173-25-004535 | 001-37708 | 251116197 | 33 | 4467 | |||
| 2025-06-26 | 8-K | 8-K | 5.02 | 0000950170-25-090205 | 001-37708 | 251075229 | 34 | 145209 | 1 | 1 |
| 2025-05-19 | 4 | 4 | 0000950170-25-074304 | 4487 | ||||||
| 2025-05-19 | 4 | 4 | 0000950170-25-074301 | 4394 | ||||||
| 2025-05-19 | 4 | 4 | 0000950170-25-074297 | 4353 | ||||||
| 2025-05-19 | 4 | 4 | 0000950170-25-074289 | 4354 | ||||||
| 2025-05-16 | 3 | 3 | 0000950170-25-073559 | 5660 | ||||||
| 2025-05-16 | 8-K | 8-K | 5.02,7.01,9.01 | 0000950170-25-073555 | 001-37708 | 25959426 | 34 | 517609 | 1 | 1 |
| 2025-05-09 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000769993-25-000250 | 005-89449 | 25929272 | 34 | 16570 | |||
| 2025-05-07 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000895421-25-000369 | 005-89449 | 25920044 | 34 | 12220 | |||
| 2025-05-05 | 10-Q | 10-Q | 0000950170-25-063518 | 001-37708 | 25912832 | 34 | 7409594 | 1 | 1 | |
| 2025-05-05 | 8-K | 8-K | 2.02,8.01,9.01 | 0000950170-25-063514 | 001-37708 | 25912781 | 34 | 407293 | 1 | 1 |
| 2025-04-17 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001576419-25-000656 | 005-89449 | 25844563 | 34 | 11009 | |||
| 2025-04-01 | ARS | ARS | 0000950170-25-048489 | 001-37708 | 25799582 | 34 | 1840932 | |||
| 2025-04-01 | DEFA14A | DEFA14A | 0000950170-25-048476 | 001-37708 | 25799546 | 34 | 866060 | |||
| 2025-04-01 | DEF 14A | DEF 14A | 0000950170-25-048472 | 001-37708 | 25799512 | 34 | 11570907 | 1 | 1 | |
| 2025-03-17 | 4 | 4 | 0000950170-25-039787 | 6556 | ||||||
| 2025-03-07 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000902219-25-000138 | 005-89449 | 25718294 | 34 | 15354 | |||
| 2025-03-06 | 4 | 4 | 0000950170-25-034634 | 8586 | ||||||
| 2025-03-04 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-001520 | 001-37708 | 25706196 | 33 | 4787 | |||
| 2025-03-04 | S-8 | S-8 | 0000950170-25-031354 | 333-285529 | 25701793 | 33 | 590154 | 1 | 1 | |
| 2025-03-03 | 10-K | 10-K | 0000950170-25-030394 | 001-37708 | 25693737 | 34 | 14912014 | 1 | 1 | |
| 2025-03-03 | 8-K | 8-K | 2.02,8.01,9.01 | 0000950170-25-030392 | 001-37708 | 25693734 | 34 | 446172 | 1 | 1 |
| 2025-02-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001085146-25-001726 | 005-89449 | 25630974 | 34 | 9428 | |||
| 2025-02-12 | 4 | 4 | 0000950170-25-019005 | 4666 | ||||||
| 2025-02-12 | 4 | 4 | 0000950170-25-019000 | 4703 | ||||||
| 2025-02-12 | 4 | 4 | 0000950170-25-018993 | 4672 | ||||||
| 2025-02-12 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0000769993-25-000129 | 005-89449 | 25613343 | 34 | 16479 | |||
| 2025-02-10 | 144 | xsl144X01/primary_doc.xml | 0001959173-25-000841 | 001-37708 | 25605461 | 33 | 4518 | |||
| 2025-02-10 | 144 | xsl144X01/primary_doc.xml | 0001959173-25-000835 | 001-37708 | 25605436 | 33 | 4603 | |||
| 2025-02-10 | 144 | xsl144X01/primary_doc.xml | 0001959173-25-000833 | 001-37708 | 25605424 | 33 | 4509 | |||
| 2025-02-07 | 4 | 4 | 0000950170-25-016391 | 9054 | ||||||
| 2025-02-07 | 4 | 4 | 0000950170-25-016389 | 9051 | ||||||
| 2025-02-07 | 4 | 4 | 0000950170-25-016384 | 9106 | ||||||
| 2025-02-07 | 4 | 4 | 0000950170-25-016380 | 4805 | ||||||
| 2025-02-07 | 4 | 4 | 0000950170-25-016374 | 4760 | ||||||
| 2025-02-07 | 4 | 4 | 0000950170-25-016369 | 4788 | ||||||
| 2025-02-07 | 4 | 4 | 0000950170-25-016363 | 4798 | ||||||
| 2025-02-07 | 4 | 4 | 0000950170-25-016357 | 4800 | ||||||
| 2025-02-07 | 4 | 4 | 0000950170-25-016351 | 4800 | ||||||
| 2025-02-07 | 4 | 4 | 0000950170-25-016346 | 4781 | ||||||
| 2025-02-05 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0000895421-25-000232 | 005-89449 | 25591242 | 34 | 11829 | |||
| 2025-01-22 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0000902664-25-000388 | 005-89449 | 25547046 | 34 | 16985 | |||
| 2024-12-20 | 8-K | 8-K | 5.02 | 0000950170-24-139121 | 001-37708 | 241568736 | 34 | 153267 | 1 | 1 |
| 2024-12-06 | SC 13G/A | us87164f1057_120624.txt | 0002012383-24-004541 | 005-89449 | 241532639 | 34 | 14017 | |||
| 2024-11-18 | 8-K | 8-K | 8.01,9.01 | 0000950170-24-127708 | 001-37708 | 241469272 | 34 | 236698 | 1 | 1 |
| 2024-11-12 | 8-K | 8-K | 8.01,9.01 | 0000950170-24-124545 | 001-37708 | 241443215 | 34 | 225476 | 1 | 1 |
| 2024-11-08 | SC 13G/A | us87164f1057_110824.txt | 0002012383-24-004032 | 005-89449 | 241442076 | 34 | 13987 | |||
| 2024-11-08 | SC 13G/A | SEC SCHEDULE 13G | 0000902219-24-000479 | 005-89449 | 241438643 | 34 | 36192 | |||
| 2024-11-05 | 10-Q | 10-Q | 0000950170-24-121439 | 001-37708 | 241427376 | 34 | 8229746 | 1 | 1 | |
| 2024-11-05 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-121437 | 001-37708 | 241427350 | 34 | 385247 | 1 | 1 |
| 2024-11-04 | 8-K | 8-K | 1.01 | 0000950170-24-120673 | 001-37708 | 241423436 | 34 | 158398 | 1 | 1 |
| 2024-10-21 | SC 13G/A | us87164f1057_102124.txt | 0002012383-24-000892 | 005-89449 | 241383520 | 34 | 13975 | |||
| 2024-10-18 | SC 13G/A | Syndax_Pharmaceuticals_Inc.htm | 0000093751-24-000879 | 005-89449 | 241379444 | 34 | 56042 | |||
| 2024-08-01 | 10-Q | 10-Q | 0000950170-24-089241 | 001-37708 | 241166495 | 34 | 7535746 | 1 | 1 | |
| 2024-08-01 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-089235 | 001-37708 | 241166446 | 34 | 372318 | 1 | 1 |
| 2024-06-17 | 4 | PRIMARY DOCUMENT | 0001562180-24-005118 | 4742 | ||||||
| 2024-05-16 | 4 | PRIMARY DOCUMENT | 0001562180-24-004087 | 5510 | ||||||
| 2024-05-16 | 3 | PRIMARY DOCUMENT | 0001562180-24-004086 | 3185 | ||||||
| 2024-05-15 | 8-K | 8-K | 5.02,5.07,7.01,9.01 | 0000950170-24-060462 | 001-37708 | 24950775 | 34 | 217271 | 1 | 1 |
| 2024-05-08 | 10-Q | 10-Q | 0000950170-24-055053 | 001-37708 | 24924199 | 34 | 6388749 | 1 | 1 | |
| 2024-05-08 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-055052 | 001-37708 | 24924191 | 34 | 341359 | 1 | 1 |
| 2024-04-02 | ARS | ARS | 0000950170-24-040230 | 001-37708 | 24814732 | 34 | 2073349 | |||
| 2024-04-02 | DEFA14A | DEFA14A | 0000950170-24-040128 | 001-37708 | 24814078 | 34 | 2056470 | |||
| 2024-04-02 | DEF 14A | DEF 14A | 0000950170-24-040099 | 001-37708 | 24814027 | 34 | 6496430 | 1 | 1 | |
| 2024-03-18 | 8-K | 8-K | 5.02,7.01,9.01 | 0000950170-24-032514 | 001-37708 | 24756901 | 34 | 469336 | 1 | 1 |
| 2024-02-27 | S-3ASR | S-3ASR | 0001193125-24-048135 | 333-277424 | 24688741 | 33 | 2234526 | |||
| 2024-02-27 | S-8 | S-8 | 0001193125-24-048118 | 333-277423 | 24688619 | 33 | 86596 | |||
| 2024-02-27 | 10-K | 10-K | 0000950170-24-021253 | 001-37708 | 24687479 | 34 | 12877333 | 1 | 1 | |
| 2024-02-27 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-021086 | 001-37708 | 24686379 | 34 | 359799 | 1 | 1 |
| 2024-02-14 | SC 13G | KYNAM CAPITAL MANAGEMENT, LP | 0001085146-24-001353 | 005-89449 | 24635177 | 34 | 44203 | |||
| 2024-02-14 | SC 13G/A | SYNDAX PHARMACEUTICALS, INC. | 0000902664-24-001533 | 005-89449 | 24632188 | 34 | 102900 | |||
| 2024-02-13 | SC 13G/A | d10978793_13g-a.htm | 0000919574-24-001234 | 005-89449 | 24631642 | 34 | 167406 | |||
| 2024-02-13 | SC 13G | SCHEDULE 13G | 0001104659-24-022051 | 005-89449 | 24629679 | 34 | 13071 | |||
| 2024-02-09 | 4 | PRIMARY DOCUMENT | 0001562180-24-001223 | 9604 | ||||||
| 2024-02-09 | 4 | PRIMARY DOCUMENT | 0001562180-24-001222 | 13064 | ||||||
| 2024-02-09 | 4 | PRIMARY DOCUMENT | 0001562180-24-001221 | 12134 | ||||||
| 2024-02-09 | 4 | PRIMARY DOCUMENT | 0001562180-24-001220 | 7744 | ||||||
| 2024-02-09 | 4 | PRIMARY DOCUMENT | 0001562180-24-001219 | 7730 | ||||||
| 2024-02-09 | 4 | PRIMARY DOCUMENT | 0001562180-24-001218 | 7860 | ||||||
| 2024-02-09 | 4 | PRIMARY DOCUMENT | 0001562180-24-001217 | 7704 | ||||||
| 2024-02-09 | 4 | PRIMARY DOCUMENT | 0001562180-24-001216 | 5155 | ||||||
| 2024-02-09 | 4 | PRIMARY DOCUMENT | 0001562180-24-001215 | 5151 | ||||||
| 2024-02-09 | 4 | PRIMARY DOCUMENT | 0001562180-24-001214 | 5130 | ||||||
| 2024-02-08 | SC 13G/A | SEC SCHEDULE 13G | 0000902219-24-000134 | 005-89449 | 24607356 | 34 | 37854 | |||
| 2024-01-25 | SC 13G/A | us87164f1057_012524.txt | 0001086364-24-003711 | 005-89449 | 24562937 | 34 | 13655 | |||
| 2024-01-25 | SC 13G/A | SyndaxPharma.txt | 0000093751-24-000236 | 005-89449 | 24560095 | 34 | 8560 | |||
| 2023-12-20 | 8-K | 8-K | 8.01,9.01 | 0000950170-23-071749 | 001-37708 | 231499465 | 34 | 224580 | 1 | 1 |
| 2023-12-15 | 8-K | 8-K | 1.01,9.01 | 0001193125-23-296814 | 001-37708 | 231491492 | 34 | 427448 | 1 | 1 |
| 2023-12-15 | 424B5 | 424B5 | 0001193125-23-296813 | 333-254661 | 231491488 | 33 | 773224 | |||
| 2023-12-14 | 424B5 | 424B5 | 0001193125-23-295515 | 333-254661 | 231487419 | 33 | 744442 | |||
| 2023-12-12 | 8-K | 8-K | 8.01,9.01 | 0000950170-23-069683 | 001-37708 | 231481236 | 34 | 363043 | 1 | 1 |
| 2023-12-07 | UPLOAD | filename1.pdf | 0000000000-23-013348 | 39667 | ||||||
| 2023-11-28 | CORRESP | filename1.htm | 0000950170-23-066397 | 299993 | ||||||
| 2023-11-13 | UPLOAD | filename1.pdf | 0000000000-23-012422 | 44691 | ||||||
| 2023-11-02 | 10-Q | 10-Q | 0000950170-23-058165 | 001-37708 | 231372208 | 34 | 9724340 | 1 | 1 | |
| 2023-11-02 | 8-K | 8-K | 2.02,9.01 | 0000950170-23-058156 | 001-37708 | 231372100 | 34 | 428610 | 1 | 1 |
| 2023-10-31 | SC 13G | SYNDAX PHARMACEUTICALS INC | 0000902664-23-005275 | 005-89449 | 231365054 | 34 | 111624 | |||
| 2023-10-05 | SC 13G/A | SC 13G/A | 0001193125-23-251311 | 005-89449 | 231310583 | 34 | 309848 | |||
| 2023-10-02 | 8-K | 8-K | 8.01,9.01 | 0000950170-23-050922 | 001-37708 | 231297695 | 34 | 240617 | 1 | 1 |
| 2023-08-10 | 4 | PRIMARY DOCUMENT | 0001562180-23-006262 | 8867 | ||||||
| 2023-08-09 | 144 | xsl144X01/primary_doc.xml | 0001950047-23-002895 | 001-37708 | 231155350 | 33 | 6230 | |||
| 2023-08-03 | 10-Q | 10-Q | 0000950170-23-037943 | 001-37708 | 231139869 | 34 | 9716402 | 1 | 1 | |
| 2023-08-03 | 8-K | 8-K | 2.02,9.01 | 0000950170-23-037936 | 001-37708 | 231139806 | 34 | 447856 | 1 | 1 |
| 2023-08-03 | 4 | PRIMARY DOCUMENT | 0001562180-23-006130 | 18994 | ||||||
| 2023-08-02 | 144 | xsl144X01/primary_doc.xml | 0001959173-23-002843 | 001-37708 | 231137430 | 33 | 5465 | |||
| 2023-07-24 | 8-K | 8-K | 8.01,9.01 | 0000950170-23-033937 | 001-37708 | 231103728 | 34 | 275949 | 1 | 1 |
| 2023-07-11 | 4 | PRIMARY DOCUMENT | 0001562180-23-005845 | 8867 | ||||||
| 2023-07-10 | 144 | xsl144X01/primary_doc.xml | 0001950047-23-002201 | 001-37708 | 231079866 | 33 | 6231 | |||
| 2023-06-14 | 4 | PRIMARY DOCUMENT | 0001562180-23-005152 | 4907 | ||||||
| 2023-06-09 | 4 | PRIMARY DOCUMENT | 0001562180-23-005057 | 14065 | ||||||
| 2023-06-09 | 144 | xsl144X01/primary_doc.xml | 0001950047-23-001446 | 001-37708 | 231005428 | 33 | 6973 | |||
| 2023-05-26 | 8-K | 8-K | 1.02,8.01,9.01 | 0000950170-23-024544 | 001-37708 | 23969841 | 34 | 723331 | 1 | 1 |
| 2023-05-26 | 424B5 | 424B5 | 0001193125-23-155499 | 333-254661 | 23969712 | 33 | 849434 | |||
| 2023-05-18 | 8-K | 8-K | 3.03,5.03,5.07,9.01 | 0000950170-23-022802 | 001-37708 | 23933147 | 34 | 228511 | 1 | 1 |
| 2023-05-10 | 4 | PRIMARY DOCUMENT | 0001562180-23-004032 | 8866 | ||||||
| 2023-05-09 | 144 | xsl144X01/primary_doc.xml | 0001950047-23-000482 | 001-37708 | 23902442 | 33 | 6265 | |||
| 2023-05-08 | 10-Q | 10-Q | 0000950170-23-018806 | 001-37708 | 23897824 | 34 | 8125502 | 1 | 1 | |
| 2023-05-08 | 8-K | 8-K | 2.02,5.02,9.01 | 0000950170-23-018794 | 001-37708 | 23897753 | 34 | 402310 | 1 | 1 |
| 2023-04-18 | DEFA14A | DEFA14A | 0000950170-23-013259 | 001-37708 | 23826761 | 34 | 72522 | |||
| 2023-04-12 | 4 | PRIMARY DOCUMENT | 0001562180-23-003521 | 8866 | ||||||
| 2023-04-12 | 4 | PRIMARY DOCUMENT | 0001562180-23-003520 | 5688 | ||||||
| 2023-04-12 | 3 | PRIMARY DOCUMENT | 0001562180-23-003519 | 3118 | ||||||
| 2023-04-07 | ARS | ARS | 0000950170-23-012192 | 001-37708 | 23808819 | 34 | 1276199 | |||
| 2023-04-07 | DEFA14A | DEFA14A | 0000950170-23-012191 | 001-37708 | 23808797 | 34 | 2083617 | |||
| 2023-04-07 | DEF 14A | DEF 14A | 0000950170-23-012189 | 001-37708 | 23808774 | 34 | 8899975 | 1 | 1 | |
| 2023-03-30 | 8-K | 8-K | 5.02,7.01,9.01 | 0000950170-23-010756 | 001-37708 | 23777192 | 34 | 547093 | 1 | 1 |
| 2023-03-28 | PRE 14A | PRE 14A | 0000950170-23-010296 | 001-37708 | 23769765 | 34 | 8911331 | 1 | 1 | |
| 2023-03-14 | 4 | PRIMARY DOCUMENT | 0001562180-23-002770 | 9077 | ||||||
| 2023-02-28 | S-8 | S-8 | 0000950170-23-005102 | 333-270093 | 23685528 | 33 | 272008 | |||
| 2023-02-28 | 10-K | 10-K | 0000950170-23-005079 | 001-37708 | 23685259 | 34 | 14425835 | 1 | 1 | |
| 2023-02-28 | 8-K | 8-K | 2.02,9.01 | 0000950170-23-005069 | 001-37708 | 23685137 | 34 | 464374 | 1 | 1 |
| 2023-02-17 | 4 | PRIMARY DOCUMENT | 0001562180-23-001533 | 14380 | ||||||
| 2023-02-14 | SC 13G/A | SC 13G/A | 0001104659-23-021838 | 005-89449 | 23630797 | 34 | 49618 | |||
| 2023-02-14 | SC 13G/A | d9942499_13g-a.htm | 0000919574-23-001638 | 005-89449 | 23628213 | 34 | 164616 | |||
| 2023-02-14 | SC 13G/A | SC 13G/A | 0001193125-23-038098 | 005-89449 | 23625338 | 34 | 329484 | |||
| 2023-02-14 | SC 13G/A | AMENDMENT NO. 7 TO THE SCHEDULE 13G | 0000921895-23-000531 | 005-89449 | 23625060 | 34 | 277033 | |||
| 2023-02-08 | 4 | PRIMARY DOCUMENT | 0001562180-23-001118 | 8940 | ||||||
| 2023-02-08 | 4 | PRIMARY DOCUMENT | 0001562180-23-001117 | 8968 | ||||||
| 2023-02-08 | 8-K | 8-K | 5.02,9.01 | 0000950170-23-002172 | 001-37708 | 23599586 | 34 | 759365 | 1 | 1 |
| 2023-02-06 | SC 13G/A | Syndax_Pharmaceuticals_Inc.txt | 0000093751-23-000262 | 005-89449 | 23590049 | 34 | 8491 | |||
| 2023-02-03 | 4 | PRIMARY DOCUMENT | 0001562180-23-000956 | 5442 | ||||||
| 2023-02-03 | 4 | PRIMARY DOCUMENT | 0001562180-23-000955 | 5466 | ||||||
| 2023-02-03 | 4 | PRIMARY DOCUMENT | 0001562180-23-000954 | 5533 | ||||||
| 2023-02-03 | 4 | PRIMARY DOCUMENT | 0001562180-23-000953 | 5407 | ||||||
| 2023-02-03 | 4 | PRIMARY DOCUMENT | 0001562180-23-000950 | 8703 | ||||||
| 2023-02-03 | 4 | PRIMARY DOCUMENT | 0001562180-23-000948 | 5439 | ||||||
| 2023-02-03 | 4 | PRIMARY DOCUMENT | 0001562180-23-000947 | 5033 | ||||||
| 2023-02-03 | 4 | PRIMARY DOCUMENT | 0001562180-23-000946 | 5028 | ||||||
| 2023-02-03 | 4 | PRIMARY DOCUMENT | 0001562180-23-000945 | 5019 | ||||||
| 2023-02-03 | 4 | PRIMARY DOCUMENT | 0001562180-23-000944 | 5012 | ||||||
| 2023-02-03 | 4 | PRIMARY DOCUMENT | 0001562180-23-000943 | 5029 | ||||||
| 2023-02-03 | 4 | PRIMARY DOCUMENT | 0001562180-23-000942 | 5028 | ||||||
| 2023-02-01 | SC 13G/A | us87164f1057_013123.txt | 0001306550-23-005951 | 005-89449 | 23573989 | 34 | 13371 | |||
| 2023-01-13 | 4 | PRIMARY DOCUMENT | 0001562180-23-000413 | 19215 | ||||||
| 2023-01-10 | SC 13G | SEC SCHEDULE 13G | 0000902219-23-000002 | 005-89449 | 23519835 | 34 | 37888 | |||
| 2022-12-14 | 8-K | 8-K | 2.02,7.01,9.01 | 0000950170-22-026546 | 001-37708 | 221462514 | 34 | 222238 | 1 | 1 |
| 2022-12-07 | 8-K | 8-K | 1.01,9.01 | 0001193125-22-300218 | 001-37708 | 221450784 | 34 | 423112 | 1 | 1 |
| 2022-12-07 | 424B5 | 424B5 | 0001193125-22-300140 | 333-254661 | 221450263 | 33 | 598419 | |||
| 2022-12-06 | 424B5 | 424B5 | 0001193125-22-299481 | 333-254661 | 221448383 | 33 | 569193 | |||
| 2022-12-05 | 4 | PRIMARY DOCUMENT | 0001562180-22-008056 | 5651 | ||||||
| 2022-12-05 | 3 | PRIMARY DOCUMENT | 0001562180-22-008047 | 3115 | ||||||
| 2022-12-05 | 8-K | 8-K | 5.02,9.01 | 0000950170-22-026017 | 001-37708 | 221443734 | 34 | 536684 | 1 | 1 |
| 2022-12-02 | 4 | PRIMARY DOCUMENT | 0001562180-22-008017 | 19433 | ||||||
| 2022-11-03 | 10-Q | 10-Q | 0000950170-22-021848 | 001-37708 | 221357970 | 34 | 10726277 | 1 | 1 | |
| 2022-11-03 | 8-K | 8-K | 2.02,9.01 | 0000950170-22-021838 | 001-37708 | 221357861 | 34 | 476684 | 1 | 1 |
| 2022-10-07 | 4 | PRIMARY DOCUMENT | 0001562180-22-007125 | 14349 | ||||||
| 2022-10-07 | 4 | PRIMARY DOCUMENT | 0001562180-22-007124 | 9058 | ||||||
| 2022-10-04 | 4 | PRIMARY DOCUMENT | 0001562180-22-007012 | 19412 | ||||||
| 2022-10-04 | 4 | PRIMARY DOCUMENT | 0001562180-22-007011 | 34929 | ||||||
| 2022-09-23 | 8-K | 8-K | 1.02,7.01,9.01 | 0000950170-22-018819 | 001-37708 | 221262370 | 34 | 183626 | 1 | 1 |
| 2022-09-21 | 4 | PRIMARY DOCUMENT | 0001562180-22-006788 | 14257 | ||||||
| 2022-09-16 | 4 | PRIMARY DOCUMENT | 0001562180-22-006706 | 24729 | ||||||
| 2022-09-16 | 4 | PRIMARY DOCUMENT | 0001562180-22-006705 | 19377 | ||||||
| 2022-08-26 | 4 | PRIMARY DOCUMENT | 0001562180-22-006334 | 15908 | ||||||
| 2022-08-09 | 4 | PRIMARY DOCUMENT | 0001562180-22-005979 | 14109 | ||||||
| 2022-08-08 | 10-Q | 10-Q | 0000950170-22-015523 | 001-37708 | 221144460 | 34 | 9749061 | 1 | 1 | |
| 2022-08-08 | 8-K | 8-K | 2.02,9.01 | 0000950170-22-015507 | 001-37708 | 221144287 | 34 | 543555 | 1 | 1 |
| 2022-07-27 | 4 | PRIMARY DOCUMENT | 0001562180-22-005761 | 14313 | ||||||
| 2022-07-08 | 4 | PRIMARY DOCUMENT | 0001562180-22-005637 | 14136 | ||||||
| 2022-07-05 | 4 | PRIMARY DOCUMENT | 0001562180-22-005475 | 8970 | ||||||
| 2022-06-15 | 4 | PRIMARY DOCUMENT | 0001562180-22-005117 | 7351 | ||||||
| 2022-06-15 | 3 | PRIMARY DOCUMENT | 0001562180-22-005116 | 3116 | ||||||
| 2022-06-13 | 8-K | 8-K | 5.02,9.01 | 0001564590-22-023045 | 001-37708 | 221010705 | 34 | 437774 | 1 | 1 |
| 2022-05-11 | 8-K | 8-K | 5.07,9.01 | 0001564590-22-019515 | 001-37708 | 22913614 | 34 | 182851 | 1 | 1 |
| 2022-05-09 | 8-K | 8-K | 2.02,9.01 | 0001564590-22-018892 | 001-37708 | 22905417 | 34 | 364830 | 1 | 1 |
| 2022-05-09 | 10-Q | 10-Q | 0001564590-22-018873 | 001-37708 | 22905051 | 34 | 8234480 | 1 | 1 | |
| 2022-04-13 | 4/A | PRIMARY DOCUMENT | 0001562180-22-003383 | 11065 | ||||||
| 2022-04-05 | 4 | PRIMARY DOCUMENT | 0001562180-22-003223 | 17560 | ||||||
| 2022-03-30 | DEFA14A | DEFA14A | 0001564590-22-012595 | 001-37708 | 22786380 | 34 | 1436669 | |||
| 2022-03-29 | DEF 14A | DEF 14A | 0001564590-22-012198 | 001-37708 | 22780710 | 34 | 2524631 | |||
| 2022-03-04 | SC 13D/A | SC 13D/A | 0001193125-22-066275 | 005-89449 | 22715069 | 34 | 135929 | |||
| 2022-03-03 | 4 | PRIMARY DOCUMENT | 0001562180-22-002258 | 5774 | ||||||
| 2022-03-03 | 3 | PRIMARY DOCUMENT | 0001562180-22-002247 | 6933 | ||||||
| 2022-03-01 | S-8 | S-8 | 0001564590-22-008120 | 333-263185 | 22699927 | 33 | 169925 | |||
| 2022-03-01 | 10-K | 10-K | 0001564590-22-008112 | 001-37708 | 22699849 | 34 | 15942998 | 1 | 1 | |
| 2022-03-01 | 8-K | 8-K | 2.02,5.02,7.01,9.01 | 0001564590-22-008030 | 001-37708 | 22697849 | 34 | 748341 | 1 | 1 |
| 2022-02-24 | 8-K | 8-K | 5.02,9.01 | 0001564590-22-006493 | 001-37708 | 22666474 | 34 | 164238 | 1 | 1 |
| 2022-02-14 | SC 13G/A | AMENDMENT NO. 6 TO THE SCHEDULE 13G | 0000921895-22-000518 | 005-89449 | 22628672 | 34 | 283560 | |||
| 2022-02-14 | SC 13G | SC 13G | 0001104659-22-021727 | 005-89449 | 22625635 | 34 | 50405 | |||
| 2022-02-14 | SC 13G/A | d9178725_13g-a.htm | 0000919574-22-001210 | 005-89449 | 22624148 | 34 | 168266 | |||
| 2022-02-10 | SC 13G/A | SYNDAX PHARMACEUTICALS, INC. | 0000902664-22-001387 | 005-89449 | 22611934 | 34 | 107620 | |||
| 2022-02-07 | SC 13G/A | us87164f1057_020722.txt | 0000834237-22-007901 | 005-89449 | 22598083 | 34 | 13371 | |||
| 2022-02-04 | SC 13G/A | SEC SCHEDULE 13G | 0001678858-22-000232 | 005-89449 | 22591435 | 34 | 33145 | |||
| 2022-02-03 | 4 | PRIMARY DOCUMENT | 0001562180-22-001081 | 5759 | ||||||
| 2022-02-03 | 4 | PRIMARY DOCUMENT | 0001562180-22-001080 | 5786 | ||||||
| 2022-02-03 | 4 | PRIMARY DOCUMENT | 0001562180-22-001079 | 8710 | ||||||
| 2022-02-03 | 4 | PRIMARY DOCUMENT | 0001562180-22-001078 | 7226 | ||||||
| 2022-02-03 | 4 | PRIMARY DOCUMENT | 0001562180-22-001077 | 8677 | ||||||
| 2022-02-03 | 4 | PRIMARY DOCUMENT | 0001562180-22-001076 | 5032 | ||||||
| 2022-02-03 | 4 | PRIMARY DOCUMENT | 0001562180-22-001074 | 5029 | ||||||
| 2022-02-03 | 4 | PRIMARY DOCUMENT | 0001562180-22-001073 | 5012 | ||||||
| 2022-02-03 | 4 | PRIMARY DOCUMENT | 0001562180-22-001072 | 5029 | ||||||
| 2022-02-03 | 4 | PRIMARY DOCUMENT | 0001562180-22-001071 | 7612 | ||||||
| 2022-02-03 | 4 | PRIMARY DOCUMENT | 0001562180-22-001070 | 5019 | ||||||
| 2022-02-03 | 4 | PRIMARY DOCUMENT | 0001562180-22-001069 | 5028 | ||||||
| 2022-02-03 | 8-K | 8-K | 5.02,7.01,9.01 | 0001564590-22-003814 | 001-37708 | 22588224 | 34 | 713389 | 1 | 1 |
| 2022-01-03 | 4 | PRIMARY DOCUMENT | 0001562180-22-000035 | 7172 | ||||||
| 2021-12-23 | SC 13G | cmw354.htm | 0000897069-21-000610 | 005-89449 | 211518207 | 34 | 163945 | |||
| 2021-12-23 | 8-K | 8-K | 1.01,2.03,9.01 | 0001564590-21-061135 | 001-37708 | 211517117 | 34 | 177279 | 1 | 1 |
| 2021-12-22 | 4 | PRIMARY DOCUMENT | 0001562180-21-007866 | 14195 | ||||||
| 2021-12-20 | 4 | PRIMARY DOCUMENT | 0001562180-21-007810 | 8843 | ||||||
| 2021-12-20 | 4 | PRIMARY DOCUMENT | 0001562180-21-007809 | 24689 | ||||||
| 2021-12-17 | 8-K | 8-K | 1.01,9.01 | 0001193125-21-361105 | 001-37708 | 211501677 | 34 | 524151 | 1 | 1 |
| 2021-12-17 | 424B5 | 424B5 | 0001193125-21-361097 | 333-254661 | 211501599 | 33 | 871142 | |||
| 2021-12-16 | 424B5 | 424B5 | 0001193125-21-358492 | 333-254661 | 211495943 | 33 | 859909 | |||
| 2021-12-15 | 4 | PRIMARY DOCUMENT | 0001562180-21-007710 | 14131 | ||||||
| 2021-12-13 | 8-K | 8-K | 8.01,9.01 | 0001564590-21-060153 | 001-37708 | 211488071 | 34 | 300443 | 1 | 1 |
| 2021-12-09 | 8-K | 8-K | 8.01,9.01 | 0001564590-21-059911 | 001-37708 | 211482733 | 34 | 214632 | 1 | 1 |
| 2021-12-09 | 424B5 | 424B5 | 0001193125-21-352755 | 333-254661 | 211482649 | 33 | 684935 | |||
| 2021-11-19 | 4 | PRIMARY DOCUMENT | 0001562180-21-007180 | 13849 | ||||||
| 2021-11-15 | 10-Q | 10-Q | 0001564590-21-057004 | 001-37708 | 211410590 | 34 | 11414627 | 1 | 1 | |
| 2021-11-15 | 8-K | 8-K | 2.02,9.01 | 0001564590-21-056999 | 001-37708 | 211410334 | 34 | 1274199 | 1 | 1 |
| 2021-11-04 | 3 | PRIMARY DOCUMENT | 0001562180-21-006828 | 16062 | ||||||
| 2021-10-27 | 4 | PRIMARY DOCUMENT | 0001562180-21-006652 | 14167 | ||||||
| 2021-10-06 | 4 | PRIMARY DOCUMENT | 0001562180-21-006357 | 4890 | ||||||
| 2021-10-04 | 8-K | 8-K | 5.02,9.01 | 0001564590-21-050013 | 001-37708 | 211302593 | 34 | 170301 | 1 | 1 |
| 2021-09-28 | 4 | PRIMARY DOCUMENT | 0001562180-21-006136 | 8777 | ||||||
| 2021-09-27 | 8-K | 8-K | 1.01,7.01,9.01 | 0001564590-21-048947 | 001-37708 | 211278895 | 34 | 278377 | 1 | 1 |
| 2021-09-22 | 4 | PRIMARY DOCUMENT | 0001562180-21-006060 | 19542 | ||||||
| 2021-09-21 | 4 | PRIMARY DOCUMENT | 0001562180-21-006038 | 14060 | ||||||
| 2021-09-17 | 4 | PRIMARY DOCUMENT | 0001562180-21-006002 | 5489 | ||||||
| 2021-09-17 | 3 | PRIMARY DOCUMENT | 0001562180-21-006001 | 5742 | ||||||
| 2021-09-15 | 8-K | 8-K | 5.02,9.01 | 0001564590-21-048050 | 001-37708 | 211255891 | 34 | 351774 | 1 | 1 |
| 2021-09-15 | 4 | PRIMARY DOCUMENT | 0001562180-21-005948 | 14165 | ||||||
| 2021-08-20 | 4 | PRIMARY DOCUMENT | 0001562180-21-005491 | 8925 | ||||||
| 2021-08-09 | 10-Q | 10-Q | 0001564590-21-042657 | 001-37708 | 211156728 | 34 | 9309996 | 1 | 1 | |
| 2021-08-09 | S-8 | S-8 | 0001564590-21-042630 | 333-258628 | 211156531 | 33 | 156983 | |||
| 2021-08-09 | 8-K | 8-K | 2.02,9.01 | 0001564590-21-042626 | 001-37708 | 211156510 | 34 | 703515 | 1 | 1 |
| 2021-05-20 | 4 | PRIMARY DOCUMENT | 0001562180-21-003670 | 13948 | ||||||
| 2021-05-13 | 8-K | 8-K | 5.07 | 0001564590-21-027518 | 001-37708 | 21919502 | 34 | 175538 | 1 | 1 |
| 2021-05-11 | 10-Q | 10-Q | 0001564590-21-026548 | 001-37708 | 21911423 | 34 | 7778791 | 1 | 1 | |
| 2021-05-11 | 8-K | 8-K | 2.02,9.01 | 0001564590-21-026549 | 001-37708 | 21911399 | 34 | 575191 | 1 | 1 |
| 2021-05-10 | SC 13G | SYNDAX PHARMACEUTICALS INC. | 0000902664-21-002667 | 005-89449 | 21907052 | 34 | 106335 | |||
| 2021-05-03 | SC 13D | SCHEDULE 13D | 0001193125-21-147745 | 005-89449 | 21883177 | 34 | 201094 | |||
| 2021-04-30 | 10-K/A | 10-K/A | 0001564590-21-022519 | 001-37708 | 21877725 | 34 | 451206 | 1 | 1 | |
| 2021-04-28 | 4 | PRIMARY DOCUMENT | 0001562180-21-002976 | 4687 | ||||||
| 2021-04-22 | 4 | PRIMARY DOCUMENT | 0001562180-21-002912 | 4790 | ||||||
| 2021-04-20 | SC 13G/A | d8844143_13g-a.htm | 0000919574-21-003048 | 005-89449 | 21838275 | 34 | 164016 | |||
| 2021-04-01 | DEF 14A | DEF 14A | 0001564590-21-017347 | 001-37708 | 21799104 | 34 | 2342349 | |||
| 2021-03-24 | S-3ASR | S-3ASR | 0001193125-21-092731 | 333-254661 | 21768843 | 33 | 1481334 | |||
| 2021-03-24 | RW | RW | 0001193125-21-092728 | 333-254574 | 21768821 | NE | 6483 | |||
| 2021-03-22 | S-3 | S-3 | 0001193125-21-089573 | 333-254574 | 21761569 | 33 | 1480775 | |||
| 2021-03-12 | 10-K | 10-K | 0001564590-21-012607 | 001-37708 | 21734614 | 34 | 12510916 | 1 | 1 | |
| 2021-03-08 | 8-K | 8-K | 2.02,9.01 | 0001564590-21-011477 | 001-37708 | 21721906 | 34 | 462304 | 1 | 1 |
| 2021-03-03 | 4 | PRIMARY DOCUMENT | 0001562180-21-001909 | 14107 | ||||||
| 2021-02-16 | SC 13G/A | SC 13G/A | 0001193125-21-044932 | 005-89449 | 21638937 | 34 | 87120 | |||
| 2021-02-16 | SC 13G/A | d8798761_13g-a.htm | 0000919574-21-001342 | 005-89449 | 21634466 | 34 | 186282 | |||
| 2021-02-12 | SC 13G/A | AMENDMENT NO. 5 TO THE SCHEDULE 13G | 0000921895-21-000391 | 005-89449 | 21629663 | 34 | 285248 | |||
| 2021-02-12 | SC 13G/A | SC 13G/A | 0001193125-21-041467 | 005-89449 | 21627252 | 34 | 172404 | |||
| 2021-02-10 | 4 | PRIMARY DOCUMENT | 0001562180-21-001044 | 8964 | ||||||
| 2021-02-05 | 8-K | 8-K | 5.02 | 0001564590-21-004514 | 001-37708 | 21596001 | 34 | 178872 | 1 | 1 |
| 2021-02-05 | 4 | PRIMARY DOCUMENT | 0001562180-21-000935 | 5434 | ||||||
| 2021-02-05 | 4 | PRIMARY DOCUMENT | 0001562180-21-000934 | 5465 | ||||||
| 2021-02-05 | 4 | PRIMARY DOCUMENT | 0001562180-21-000933 | 5400 | ||||||
| 2021-02-05 | 4 | PRIMARY DOCUMENT | 0001562180-21-000932 | 7223 | ||||||
| 2021-02-05 | 4 | PRIMARY DOCUMENT | 0001562180-21-000931 | 8981 | ||||||
| 2021-02-05 | 4 | PRIMARY DOCUMENT | 0001562180-21-000930 | 5033 | ||||||
| 2021-02-05 | 4 | PRIMARY DOCUMENT | 0001562180-21-000929 | 5020 | ||||||
| 2021-02-05 | 4 | PRIMARY DOCUMENT | 0001562180-21-000928 | 5013 | ||||||
| 2021-02-05 | 4 | PRIMARY DOCUMENT | 0001562180-21-000925 | 5030 | ||||||
| 2021-02-05 | 4 | PRIMARY DOCUMENT | 0001562180-21-000927 | 5030 | ||||||
| 2021-02-05 | 4 | PRIMARY DOCUMENT | 0001562180-21-000926 | 5029 | ||||||
| 2021-02-04 | SC 13G/A | SEC SCHEDULE 13G | 0000902219-21-000181 | 005-89449 | 21589452 | 34 | 37615 | |||
| 2021-02-04 | SC 13G/A | SC 13G/A | 0001193125-21-027666 | 005-89449 | 21588317 | 34 | 114424 | |||
| 2021-02-03 | 4 | PRIMARY DOCUMENT | 0001562180-21-000869 | 8933 | ||||||
| 2021-02-02 | SC 13G | us87164f1057_020221.txt | 0000834237-21-007058 | 005-89449 | 21580839 | 34 | 13215 | |||
| 2021-01-21 | SC 13G/A | SCHEDULE 13G/A FOR SYNDAX PHARMACEUTICALS, INC. ON BEHALF OF DOMAIN PARTNERS VII | 0000904454-21-000041 | 005-89449 | 21540088 | 34 | 61766 | |||
| 2020-12-10 | SC 13G/A | SEC SCHEDULE 13G | 0000902219-20-000443 | 005-89449 | 201379522 | 34 | 33368 | |||
| 2020-12-09 | 8-K | 8-K | 1.01,9.01 | 0001193125-20-313808 | 001-37708 | 201377891 | 34 | 424807 | 1 | 1 |
| 2020-12-09 | 424B5 | 424B5 | 0001193125-20-313801 | 333-233564 | 201377870 | 33 | 996696 | |||
| 2020-12-07 | 8-K | 8-K | 1.02,8.01,9.01 | 0001193125-20-311904 | 001-37708 | 201373566 | 34 | 279536 | 1 | 1 |
| 2020-12-07 | 424B5 | 424B5 | 0001193125-20-311899 | 333-233564 | 201373543 | 33 | 720846 | |||
| 2020-12-03 | 4 | PRIMARY DOCUMENT | 0001562180-20-007070 | 8816 | ||||||
| 2020-11-25 | 4 | PRIMARY DOCUMENT | 0001562180-20-006920 | 15367 | ||||||
| 2020-11-12 | 4 | PRIMARY DOCUMENT | 0001562180-20-006681 | 14002 | ||||||
| 2020-11-06 | 4 | PRIMARY DOCUMENT | 0001562180-20-006583 | 8546 | ||||||
| 2020-11-05 | 10-Q | 10-Q | 0001564590-20-051287 | 001-37708 | 201290352 | 34 | 10503573 | 1 | 1 | |
| 2020-11-04 | SC 13G | d8641259_13g.htm | 0000919574-20-006675 | 005-89449 | 201287485 | 34 | 201361 | |||
| 2020-11-02 | 8-K | 8-K | 2.02,9.01 | 0001564590-20-049638 | 001-37708 | 201280521 | 34 | 423983 | 1 | 1 |
| 2020-09-09 | SC 13G/A | us87164f1057_090920.txt | 0000834237-20-010194 | 005-89449 | 201166510 | 34 | 12260 | |||
| 2020-08-06 | 10-Q | 10-Q | 0001564590-20-037777 | 001-37708 | 201082031 | 34 | 9463584 | 1 | 1 | |
| 2020-08-06 | S-8 | S-8 | 0001564590-20-037767 | 333-241654 | 201081936 | 33 | 142980 | |||
| 2020-08-06 | 8-K | 8-K | 2.02,9.01 | 0001564590-20-037719 | 001-37708 | 201081559 | 34 | 445980 | 1 | 1 |
| 2020-07-13 | 3 | PRIMARY DOCUMENT | 0001562180-20-005102 | 4507 | ||||||
| 2020-07-08 | 4 | PRIMARY DOCUMENT | 0001562180-20-005074 | 4879 | ||||||
| 2020-07-07 | 8-K | 8-K | 5.02,9.01 | 0001564590-20-031882 | 001-37708 | 201015222 | 34 | 219184 | ||
| 2020-06-09 | 8-K | 8-K | 5.07 | 0001564590-20-028764 | 001-37708 | 20951814 | 34 | 35530 | ||
| 2020-05-11 | SC 13G | SC 13G | 0001193125-20-139263 | 005-89449 | 20866031 | 34 | 108450 | |||
| 2020-05-07 | 10-Q | 10-Q | 0001564590-20-022971 | 001-37708 | 20857286 | 34 | 8097293 | 1 | ||
| 2020-05-07 | 8-K | 8-K | 2.02,9.01 | 0001564590-20-022849 | 001-37708 | 20856406 | 34 | 262646 | ||
| 2020-05-04 | 8-K | 8-K | 1.01,8.01,9.01 | 0001564590-20-020633 | 001-37708 | 20842919 | 34 | 457729 | ||
| 2020-05-04 | 424B5 | 424B5 | 0001564590-20-020574 | 333-233564 | 20842274 | 33 | 1243631 | |||
| 2020-04-30 | 8-K | 8-K | 2.02,8.01,9.01 | 0001564590-20-019941 | 001-37708 | 20833056 | 34 | 555524 | ||
| 2020-04-30 | 424B5 | 424B5 | 0001564590-20-019928 | 333-233564 | 20833014 | 33 | 1283549 | |||
| 2020-04-29 | DEF 14A | DEF 14A | 0001564590-20-019694 | 001-37708 | 20830166 | 34 | 1248442 | |||
| 2020-03-05 | 10-K | 10-K | 0001564590-20-009016 | 001-37708 | 20691835 | 34 | 9979233 | 1 | ||
| 2020-03-03 | 8-K | 8-K | 2.02,9.01 | 0001564590-20-008426 | 001-37708 | 20682063 | 34 | 279141 | ||
| 2020-02-20 | 8-K | 8-K | 5.02 | 0001564590-20-005551 | 001-37708 | 20635030 | 34 | 48765 | ||
| 2020-02-14 | SC 13G/A | AMENDMENT NO. 4 TO THE SCHEDULE 13G | 0000921895-20-000574 | 005-89449 | 20621956 | 34 | 307900 | |||
| 2020-02-14 | 4 | PRIMARY DOCUMENT | 0001562180-20-001238 | 7092 | ||||||
| 2020-02-14 | 4 | PRIMARY DOCUMENT | 0001562180-20-001237 | 8957 | ||||||
| 2020-02-14 | 4 | PRIMARY DOCUMENT | 0001562180-20-001236 | 5468 | ||||||
| 2020-02-14 | 4 | PRIMARY DOCUMENT | 0001562180-20-001235 | 5463 | ||||||
| 2020-02-14 | 4 | PRIMARY DOCUMENT | 0001562180-20-001234 | 5464 | ||||||
| 2020-02-14 | 4 | PRIMARY DOCUMENT | 0001562180-20-001233 | 5305 | ||||||
| 2020-02-14 | 4 | PRIMARY DOCUMENT | 0001562180-20-001232 | 5304 |
One latest value per concept from companyfacts (325 concepts). Full history stays in the JSON.
| Taxonomy | Tag | Label | Unit | Value | Start | End | FY | FP | Form | Filed | Accn |
|---|---|---|---|---|---|---|---|---|---|---|---|
| dei | EntityCommonStockSharesOutstanding | Entity Common Stock, Shares Outstanding | shares | 89.30M | 2026-07-31 | 2026 | Q2 | 10-Q | 2026-08-04 | 0001193125-26-332750 | |
| dei | EntityPublicFloat | Entity Public Float | USD | 799.20M | 2025-06-30 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 | |
| ecd | CoSelectedMeasureAmt | CoSelectedMeasureAmt | USDPerShare | 21.01 | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-30 | 0001193125-26-197859 | ||
| ecd | NonPeoNeoAvgCompActuallyPaidAmt | NonPeoNeoAvgCompActuallyPaidAmt | USD | 3.61M | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-30 | 0001193125-26-197859 | ||
| ecd | NonPeoNeoAvgTotalCompAmt | NonPeoNeoAvgTotalCompAmt | USD | 2.45M | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-30 | 0001193125-26-197859 | ||
| ecd | PeerGroupTotalShareholderRtnAmt | PeerGroupTotalShareholderRtnAmt | USD | 124.75 | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-30 | 0001193125-26-197859 | ||
| ecd | TotalShareholderRtnAmt | TotalShareholderRtnAmt | USD | 94.47 | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-30 | 0001193125-26-197859 | ||
| us-gaap | AccountsAndOtherReceivablesNetCurrent | Accounts and Other Receivables, Net, Current | USD | 46.87M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | AccountsPayableCurrent | Accounts Payable, Current | USD | 3.57M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | AccountsReceivableNetCurrent | Accounts Receivable, after Allowance for Credit Loss, Current | USD | 38.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 | |
| us-gaap | AccretionAmortizationOfDiscountsAndPremiumsInvestments | Accretion (Amortization) of Discounts and Premiums, Investments | USD | 3.16M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | AccruedLiabilitiesAndOtherLiabilities | Accrued Liabilities and Other Liabilities | USD | 116.86M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | AccruedProfessionalFeesCurrent | Accrued Professional Fees, Current | USD | 37.69M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment | Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | USD | 440,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax | AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax | USD | -1.67M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | AdditionalPaidInCapital | Additional Paid in Capital | USD | 484.89M | 2018-09-30 | 2018 | Q3 | 10-Q | 2018-11-05 | 0001564590-18-026892 | |
| us-gaap | AdditionalPaidInCapitalCommonStock | Additional Paid in Capital, Common Stock | USD | 1.63B | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | AdjustmentOfWarrantsGrantedForServices | Adjustment of Warrants Granted for Services | USD | -1,000 | 2023-04-01 | 2023-06-30 | 2023 | Q3 | 10-Q | 2023-11-02 | 0000950170-23-058165 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue | APIC, Share-based Payment Arrangement, Increase for Cost Recognition | USD | 15.48M | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | USD | 7.19M | 2016-01-01 | 2016-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001564590-19-006772 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalStockSplit | Adjustments to Additional Paid in Capital, Stock Split | USD | 1,000 | 2016-01-01 | 2016-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001564590-19-006772 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalWarrantIssued | Adjustments to Additional Paid in Capital, Warrant Issued | USD | 16.78M | 2018-01-01 | 2018-12-31 | 2020 | FY | 10-K | 2021-03-12 | 0001564590-21-012607 |
| us-gaap | AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net | USD | 92,000 | 2022-01-01 | 2022-03-31 | 2022 | Q1 | 10-Q | 2022-05-09 | 0001564590-22-018873 |
| us-gaap | AdvertisingExpense | Advertising Expense | USD | 14.40M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | AllocatedShareBasedCompensationExpense | Share-based Payment Arrangement, Expense | USD | 41.35M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | AllowanceForDoubtfulAccountsReceivable | Accounts Receivable, Allowance for Credit Loss | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 | |
| us-gaap | AmortizationOfFinancingCosts | Amortization of Debt Issuance Costs | USD | 538,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | AmortizationOfFinancingCostsAndDiscounts | Amortization of Debt Issuance Costs and Discounts | USD | 762,000 | 2015-01-01 | 2015-12-31 | 2017 | FY | 10-K | 2018-03-08 | 0001564590-18-004911 |
| us-gaap | Assets | Assets | USD | 692.67M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | AssetsCurrent | Assets, Current | USD | 567.44M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | USD | 1.67M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | AvailableForSaleDebtSecuritiesAmortizedCostBasis | Debt Securities, Available-for-sale, Amortized Cost | USD | 416.81M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | AvailableForSaleSecuritiesDebtSecurities | Debt Securities, Available-for-sale | USD | 415.14M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | AvailableForSaleSecuritiesGrossRealizedGainLossNet | Available-for-sale Securities, Gross Realized Gain (Loss) | USD | 0 | 2018-01-01 | 2018-06-30 | 2018 | Q2 | 10-Q | 2018-08-08 | 0001564590-18-020483 |
| us-gaap | BusinessCombinationContingentConsiderationLiability | Business Combination, Contingent Consideration, Liability | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | CapitalExpendituresIncurredButNotYetPaid | Capital Expenditures Incurred but Not yet Paid | USD | 42,000 | 2017-01-01 | 2017-09-30 | 2018 | Q3 | 10-Q | 2018-11-05 | 0001564590-18-026892 |
| us-gaap | CapitalLeasesFutureMinimumPaymentsDue | Capital Leases, Future Minimum Payments Due | USD | 13,000 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001564590-19-006772 | |
| us-gaap | CapitalLeasesFutureMinimumPaymentsDueCurrent | Capital Leases, Future Minimum Payments Due, Next Twelve Months | USD | 4,000 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001564590-19-006772 | |
| us-gaap | CapitalLeasesFutureMinimumPaymentsDueInFiveYears | Capital Leases, Future Minimum Payments Due in Five Years | USD | 0 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001564590-19-006772 | |
| us-gaap | CapitalLeasesFutureMinimumPaymentsDueInFourYears | Capital Leases, Future Minimum Payments Due in Four Years | USD | 1,000 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001564590-19-006772 | |
| us-gaap | CapitalLeasesFutureMinimumPaymentsDueInThreeYears | Capital Leases, Future Minimum Payments Due in Three Years | USD | 4,000 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001564590-19-006772 | |
| us-gaap | CapitalLeasesFutureMinimumPaymentsDueInTwoYears | Capital Leases, Future Minimum Payments Due in Two Years | USD | 4,000 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001564590-19-006772 | |
| us-gaap | CapitalLeasesFutureMinimumPaymentsDueThereafter | Capital Leases, Future Minimum Payments Due Thereafter | USD | 0 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001564590-19-006772 | |
| us-gaap | CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments | Capital Leases, Future Minimum Payments, Interest Included in Payments | USD | 2,000 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001564590-19-006772 | |
| us-gaap | CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments | Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments | USD | 11,000 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001564590-19-006772 | |
| us-gaap | CashAndCashEquivalentsAtCarryingValue | Cash and Cash Equivalents, at Carrying Value | USD | 135.94M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | CashAndCashEquivalentsPeriodIncreaseDecrease | Cash and Cash Equivalents, Period Increase (Decrease) | USD | 11.32M | 2017-01-01 | 2017-12-31 | 2017 | FY | 10-K | 2018-03-08 | 0001564590-18-004911 |
| us-gaap | CashCashEquivalentsAndShortTermInvestments | Cash, Cash Equivalents, and Short-term Investments | USD | 113.20M | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-09 | 0001564590-18-012378 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | USD | 28.20M | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-09 | 0001564590-18-012378 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | USD | 136.04M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | USD | 1.01M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 | Class of Warrant or Right, Exercise Price of Warrants or Rights | USD/shares | 0 | 2019-03-31 | 2019 | Q3 | 10-Q | 2019-11-07 | 0001564590-19-041719 | |
| us-gaap | CommonStockCapitalSharesReservedForFutureIssuance | Common Stock, Capital Shares Reserved for Future Issuance | shares | 30.34M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 | |
| us-gaap | CommonStockParOrStatedValuePerShare | Common Stock, Par or Stated Value Per Share | USD/shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | CommonStockSharesAuthorized | Common Stock, Shares Authorized | shares | 200.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | CommonStockSharesIssued | Common Stock, Shares, Issued | shares | 89.99M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | CommonStockSharesOutstanding | Common Stock, Shares, Outstanding | shares | 89.99M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | CommonStockValue | Common Stock, Value, Issued | USD | 9,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | ComprehensiveIncomeNetOfTax | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | USD | -285.13M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | ContractWithCustomerLiabilityCurrent | Contract with Customer, Liability, Current | USD | 1.52M | 2020-12-31 | 2021 | FY | 10-K | 2022-03-01 | 0001564590-22-008112 | |
| us-gaap | ContractWithCustomerLiabilityNoncurrent | Contract with Customer, Liability, Noncurrent | USD | 11.62M | 2020-12-31 | 2021 | FY | 10-K | 2022-03-01 | 0001564590-22-008112 | |
| us-gaap | ConversionOfStockAmountConverted1 | Conversion of Stock, Amount Converted | USD | 328.94M | 2016-01-01 | 2016-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001564590-19-006772 |
| us-gaap | ConvertibleLongTermNotesPayable | Convertible Notes Payable, Noncurrent | USD | 244.19M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | DebtConversionConvertedInstrumentAmount1 | Debt Conversion, Converted Instrument, Amount | USD | 5.21M | 2015-01-01 | 2015-12-31 | 2017 | FY | 10-K | 2018-03-08 | 0001564590-18-004911 |
| us-gaap | DebtCurrent | Debt, Current | USD | 344.10M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | DebtInstrumentCarryingAmount | Long-term Debt, Gross | USD | 20.00M | 2022-06-30 | 2022 | Q2 | 10-Q | 2022-08-08 | 0000950170-22-015523 | |
| us-gaap | DebtInstrumentFaceAmount | Debt Instrument, Face Amount | USD | 5.00M | 2014-09-30 | 2017 | FY | 10-K | 2018-03-08 | 0001564590-18-004911 | |
| us-gaap | DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction | Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction | USD | 250,000 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-02-27 | 0000950170-24-021253 |
| us-gaap | DebtSecuritiesAvailableForSaleRealizedGainLoss | Debt Securities, Available-for-sale, Realized Gain (Loss) | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | DecreaseInRestrictedCash | Decrease in Restricted Cash | USD | 2,000 | 2016-01-01 | 2016-03-31 | 2016 | Q1 | 10-Q | 2016-05-16 | 0001193125-16-591861 |
| us-gaap | DeferredFinanceCostsNet | Debt Issuance Costs, Net | USD | 5.91M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | DeferredOfferingCosts | Deferred Offering Costs | USD | 0 | 2017-09-30 | 2017 | Q3 | 10-Q | 2017-11-08 | 0001193125-17-336444 | |
| us-gaap | DeferredRevenueCurrent | Deferred Revenue, Current | USD | 1.52M | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-09 | 0001564590-18-012378 | |
| us-gaap | DeferredRevenueNoncurrent | Deferred Revenue, Noncurrent | USD | 15.79M | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-09 | 0001564590-18-012378 | |
| us-gaap | DeferredTaxAssetInterestCarryforward | Deferred Tax Asset, Interest Carryforward | USD | 2.49M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 | |
| us-gaap | DeferredTaxAssetsDeferredIncome | Deferred Tax Assets, Deferred Income | USD | 2.99M | 2020-12-31 | 2021 | FY | 10-K | 2022-03-01 | 0001564590-22-008112 | |
| us-gaap | DeferredTaxAssetsGross | Deferred Tax Assets, Gross | USD | 339.71M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 | |
| us-gaap | DeferredTaxAssetsInProcessResearchAndDevelopment | Deferred Tax Assets, in Process Research and Development | USD | 13.52M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 | |
| us-gaap | DeferredTaxAssetsLiabilitiesNet | Deferred Tax Assets, Net | USD | 79.60M | 2023-12-31 | 2023 | FY | 10-K | 2024-02-27 | 0000950170-24-021253 | |
| us-gaap | DeferredTaxAssetsNet | Deferred Tax Assets, Net of Valuation Allowance | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwards | Deferred Tax Assets, Operating Loss Carryforwards | USD | 135.52M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwardsDomestic | Deferred Tax Assets, Operating Loss Carryforwards, Domestic | USD | 585.30M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal | Deferred Tax Assets, Operating Loss Carryforwards, State and Local | USD | 227.70M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 | |
| us-gaap | DeferredTaxAssetsOther | Deferred Tax Assets, Other | USD | 1.26M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 | |
| us-gaap | DeferredTaxAssetsTaxCreditCarryforwardsOther | Deferred Tax Assets, Tax Credit Carryforwards, Other | USD | 26.99M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpense | Deferred Tax Assets, Tax Deferred Expense | USD | 53.70M | 2023-12-31 | 2023 | FY | 10-K | 2024-02-27 | 0000950170-24-021253 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | USD | 15.35M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities | Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities | USD | 5.02M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 | |
| us-gaap | DeferredTaxAssetsValuationAllowance | Deferred Tax Assets, Valuation Allowance | USD | 339.71M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 | |
| us-gaap | DefinedContributionPlanEmployerDiscretionaryContributionAmount | Defined Contribution Plan, Employer Discretionary Contribution Amount | USD | 3.10M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | DepositLiabilitiesAccruedInterest | Deposit Liabilities, Accrued Interest | USD | 4.93M | 2024-12-31 | 2024 | FY | 10-K | 2025-03-03 | 0000950170-25-030394 | |
| us-gaap | DepositsAssetsCurrent | Deposits Assets, Current | USD | 10.15M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | Depreciation | Depreciation | USD | 15.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | DepreciationAmortizationAndAccretionNet | Depreciation, Amortization and Accretion, Net | USD | -580,000 | 2019-01-01 | 2019-09-30 | 2019 | Q3 | 10-Q | 2019-11-07 | 0001564590-19-041719 |
| us-gaap | DerivativeGainLossOnDerivativeNet | Derivative, Gain (Loss) on Derivative, Net | USD | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-03 | 0000950170-25-030394 |
| us-gaap | DerivativeLiabilitiesCurrent | Derivative Liability, Current | USD | 0 | 2022-12-31 | 2022 | FY | 10-K | 2023-02-28 | 0000950170-23-005079 | |
| us-gaap | EarningsPerShareBasic | Earnings Per Share, Basic | USD/shares | -1.59 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | EarningsPerShareBasicAndDiluted | Earnings Per Share, Basic and Diluted | USD/shares | -0.63 | 2022-01-01 | 2022-03-31 | 2022 | Q1 | 10-Q | 2022-05-09 | 0001564590-22-018873 |
| us-gaap | EarningsPerShareDiluted | Earnings Per Share, Diluted | USD/shares | -1.59 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | EffectiveIncomeTaxRateContinuingOperations | Effective Income Tax Rate Reconciliation, Percent | pure | -0.002 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | pure | 0.21 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent | pure | -0.273 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpense | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent | pure | -0.011 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent | pure | -0.001 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent | pure | -0.011 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | EffectiveIncomeTaxRateReconciliationOtherAdjustments | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent | pure | -0.001 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent | pure | -0.001 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxCredits | Effective Income Tax Rate Reconciliation, Tax Credit, Percent | pure | -0.011 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxCreditsOther | Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent | pure | -0.095 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxCreditsResearch | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent | pure | -0.009 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | EmployeeRelatedLiabilitiesCurrent | Employee-related Liabilities, Current | USD | 14.16M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | FairValueAdjustmentOfWarrants | Fair Value Adjustment of Warrants | USD | 1.70M | 2016-01-01 | 2016-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001564590-19-006772 |
| us-gaap | FairValueAssumptionsExpectedDividendRate | Fair Value Assumptions, Expected Dividend Rate (Deprecated 2018-01-31) | pure | 0 | 2017-01-01 | 2017-12-31 | 2017 | FY | 10-K | 2018-03-08 | 0001564590-18-004911 |
| us-gaap | FairValueAssumptionsExpectedVolatilityRate | Fair Value Assumptions, Expected Volatility Rate (Deprecated 2018-01-31) | pure | 0.739 | 2017-01-01 | 2017-12-31 | 2017 | FY | 10-K | 2018-03-08 | 0001564590-18-004911 |
| us-gaap | FairValueAssumptionsRiskFreeInterestRate | Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) | pure | 0.02 | 2017-01-01 | 2017-12-31 | 2017 | FY | 10-K | 2018-03-08 | 0001564590-18-004911 |
| us-gaap | FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value | USD | 187,000 | 2021-12-31 | 2022 | FY | 10-K | 2023-02-28 | 0000950170-23-005079 | |
| us-gaap | FinanceLeaseLiabilityPaymentsDue | Finance Lease, Liability, Payment, Due | USD | 2.24M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 | |
| us-gaap | GeneralAndAdministrativeExpense | General and Administrative Expense | USD | 122.84M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | IncomeTaxesPaidNet | Income Taxes Paid, Net | USD | 150 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | IncomeTaxExpenseBenefit | Income Tax Expense (Benefit) | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | USD | 77.52M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount | USD | -59.83M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | IncomeTaxReconciliationNondeductibleExpense | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount | USD | 3.23M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | IncomeTaxReconciliationNondeductibleExpenseOther | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount | USD | 202,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount | USD | 3.06M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | IncomeTaxReconciliationOtherAdjustments | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount | USD | 363,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | IncomeTaxReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount | USD | 342,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | IncomeTaxReconciliationTaxCreditsOther | Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount | USD | 26.99M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | IncomeTaxReconciliationTaxCreditsResearch | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount | USD | 2.53M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | IncreaseDecreaseInAccountsPayable | Increase (Decrease) in Accounts Payable | USD | -13.01M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | IncreaseDecreaseInAccountsReceivable | Increase (Decrease) in Accounts Receivable | USD | 8.87M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets | Increase (Decrease) in Accounts Receivable and Other Operating Assets | USD | -5.71M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities | USD | 11.69M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | IncreaseDecreaseInContractWithCustomerLiability | Increase (Decrease) in Contract with Customer, Liability | USD | 0 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-02-27 | 0000950170-24-021253 |
| us-gaap | IncreaseDecreaseInDeferredRevenue | Increase (Decrease) in Deferred Revenue | USD | -379,000 | 2018-01-01 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-09 | 0001564590-18-012378 |
| us-gaap | IncreaseDecreaseInInventories | Increase (Decrease) in Inventories | USD | 6.24M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | IncreaseDecreaseInOtherCurrentAssets | Increase (Decrease) in Other Current Assets | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | IncreaseDecreaseInOtherOperatingAssets | Increase (Decrease) in Other Operating Assets | USD | -463,000 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-03 | 0000950170-25-030394 |
| us-gaap | IncreaseDecreaseInOtherReceivables | Increase (Decrease) in Other Receivables | USD | 13.10M | 2022-01-01 | 2022-06-30 | 2022 | Q2 | 10-Q | 2022-08-08 | 0000950170-22-015523 |
| us-gaap | IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets | Increase (Decrease) in Prepaid Expense and Other Assets | USD | -8.87M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | IncreaseDecreaseInRestrictedCash | Increase (Decrease) in Restricted Cash | USD | -45,000 | 2017-01-01 | 2017-12-31 | 2017 | FY | 10-K | 2018-03-08 | 0001564590-18-004911 |
| us-gaap | IncrementalCommonSharesAttributableToShareBasedPaymentArrangements | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements | shares | 1.56M | 2021-01-01 | 2021-12-31 | 2023 | FY | 10-K | 2024-02-27 | 0000950170-24-021253 |
| us-gaap | InterestExpense | Interest Expense | USD | 100,000 | 2024-01-01 | 2024-06-30 | 2024 | Q2 | 10-Q | 2024-08-01 | 0000950170-24-089241 |
| us-gaap | InterestExpenseNonoperating | InterestExpenseNonoperating | USD | 4,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | InterestIncomeExpenseNonoperatingNet | Interest Income (Expense), Nonoperating, Net | USD | 1.57M | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-05 | 0001564590-20-009016 |
| us-gaap | InterestPaid | Interest Paid, Including Capitalized Interest, Operating and Investing Activities | USD | 2,000 | 2016-01-01 | 2016-12-31 | 2017 | FY | 10-K | 2018-03-08 | 0001564590-18-004911 |
| us-gaap | InterestPaidNet | Interest Paid, Excluding Capitalized Interest, Operating Activities | USD | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-03 | 0000950170-25-030394 |
| us-gaap | InterestPayableCurrent | Interest Payable, Current | USD | 1.72M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | InterestReceivableCurrent | Interest Receivable, Current | USD | 3.07M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | InventoryFinishedGoods | Inventory, Finished Goods, Gross | USD | 1.17M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | InventoryGross | Inventory, Gross | USD | 32.75M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 | |
| us-gaap | InventoryNet | Inventory, Net | USD | 39.38M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | InventoryRawMaterials | Inventory, Raw Materials, Gross | USD | 34.87M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | InventoryValuationReserves | Inventory Valuation Reserves | USD | 200,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 | |
| us-gaap | InventoryWorkInProcess | Inventory, Work in Process, Gross | USD | 3.34M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | InvestmentIncomeInterest | Investment Income, Interest | USD | 12.90M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDue | Lessee, Operating Lease, Liability, to be Paid | USD | 1.74M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths | Lessee, Operating Lease, Liability, to be Paid, Year One | USD | 656,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearFour | Lessee, Operating Lease, Liability, to be Paid, Year Four | USD | 59,000 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-05 | 0001564590-20-009016 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearThree | Lessee, Operating Lease, Liability, to be Paid, Year Three | USD | 403,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearTwo | Lessee, Operating Lease, Liability, to be Paid, Year Two | USD | 676,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear | Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year | USD | 142,000 | 2019-09-30 | 2019 | Q3 | 10-Q | 2019-11-07 | 0001564590-19-041719 | |
| us-gaap | LesseeOperatingLeaseLiabilityUndiscountedExcessAmount | Lessee, Operating Lease, Liability, Undiscounted Excess Amount | USD | 214,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 | |
| us-gaap | Liabilities | Liabilities | USD | 709.85M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | LiabilitiesAndStockholdersEquity | Liabilities and Equity | USD | 692.67M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | LiabilitiesCurrent | Liabilities, Current | USD | 120.96M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | LiabilitiesNoncurrent | Liabilities, Noncurrent | USD | 588.89M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | LicensesRevenue | Licenses Revenue (Deprecated 2018-01-31) | USD | 379,000 | 2018-01-01 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-09 | 0001564590-18-012378 |
| us-gaap | LoansPayable | Loans Payable | USD | 20.21M | 2022-06-30 | 2022 | Q2 | 10-Q | 2022-08-08 | 0000950170-22-015523 | |
| us-gaap | LoansPayableCurrent | Loans Payable, Current | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | LoansPayableToBankCurrent | Loans Payable to Bank, Current | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 | |
| us-gaap | LongTermDebtCurrent | Long-term Debt, Current Maturities | USD | 350.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths | Long-Term Debt, Maturity, Year One | USD | 14.77M | 2022-06-30 | 2022 | Q2 | 10-Q | 2022-08-08 | 0000950170-22-015523 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour | Long-Term Debt, Maturity, Year Four | USD | 7.13M | 2020-06-30 | 2020 | Q2 | 10-Q | 2020-08-06 | 0001564590-20-037777 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree | Long-Term Debt, Maturity, Year Three | USD | 5.24M | 2021-12-31 | 2021 | FY | 10-K | 2022-03-01 | 0001564590-22-008112 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo | Long-Term Debt, Maturity, Year Two | USD | 5.24M | 2022-06-30 | 2022 | Q2 | 10-Q | 2022-08-08 | 0000950170-22-015523 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear | Long-Term Debt, Maturity, Remainder of Fiscal Year | USD | 0 | 2022-06-30 | 2022 | Q2 | 10-Q | 2022-08-08 | 0000950170-22-015523 | |
| us-gaap | LongTermInvestments | Long-term Investments | USD | 123.97M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | LongTermLoansPayable | Loans Payable, Noncurrent | USD | 0 | 2022-12-31 | 2022 | FY | 10-K | 2023-02-28 | 0000950170-23-005079 | |
| us-gaap | LongTermNotesPayable | Notes Payable, Noncurrent | USD | 331.56M | 2024-12-31 | 2024 | FY | 10-K | 2025-03-03 | 0000950170-25-030394 | |
| us-gaap | LossContingencyLossInPeriod | Loss Contingency, Loss in Period | USD | 0 | 2026-01-01 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-04-30 | 0001193125-26-197154 |
| us-gaap | MarketableSecuritiesUnrealizedGainLoss | Marketable Securities, Unrealized Gain (Loss) | USD | -28,000 | 2017-01-01 | 2017-09-30 | 2017 | Q3 | 10-Q | 2017-11-08 | 0001193125-17-336444 |
| us-gaap | NetCashProvidedByUsedInFinancingActivities | Net Cash Provided by (Used in) Financing Activities | USD | 263.88M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | NetCashProvidedByUsedInFinancingActivitiesContinuingOperations | Net Cash Provided by (Used in) Financing Activities, Continuing Operations | USD | 33,000 | 2018-01-01 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-09 | 0001564590-18-012378 |
| us-gaap | NetCashProvidedByUsedInInvestingActivities | Net Cash Provided by (Used in) Investing Activities | USD | -155.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | NetCashProvidedByUsedInInvestingActivitiesContinuingOperations | Net Cash Provided by (Used in) Investing Activities, Continuing Operations | USD | 12.64M | 2018-01-01 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-09 | 0001564590-18-012378 |
| us-gaap | NetCashProvidedByUsedInOperatingActivities | Net Cash Provided by (Used in) Operating Activities | USD | -107.87M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | NetCashProvidedByUsedInOperatingActivitiesContinuingOperations | Net Cash Provided by (Used in) Operating Activities, Continuing Operations | USD | -19.87M | 2018-01-01 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-09 | 0001564590-18-012378 |
| us-gaap | NetIncomeLoss | Net Income (Loss) Attributable to Parent | USD | -141.47M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | NetIncomeLossAvailableToCommonStockholdersBasic | Net Income (Loss) Available to Common Stockholders, Basic | USD | -141.47M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | NetIncomeLossAvailableToCommonStockholdersDiluted | Net Income (Loss) Available to Common Stockholders, Diluted | USD | -141.47M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | NonoperatingIncomeExpense | Nonoperating Income (Expense) | USD | -25.38M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | NumberOfOperatingSegments | Number of Operating Segments | Segment | 1 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | NumberOfReportableSegments | Number of Reportable Segments | Segment | 1 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | OperatingExpenses | Operating Expenses | USD | 337.04M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | OperatingIncomeLoss | Operating Income (Loss) | USD | -116.09M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | OperatingLeaseExpense | Operating Lease, Expense | USD | 900,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | OperatingLeaseLiability | Operating Lease, Liability | USD | 1.52M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 | |
| us-gaap | OperatingLeaseLiabilityCurrent | Operating Lease, Liability, Current | USD | 526,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | OperatingLeaseLiabilityNoncurrent | Operating Lease, Liability, Noncurrent | USD | 1.58M | 2024-12-31 | 2024 | FY | 10-K | 2025-03-03 | 0000950170-25-030394 | |
| us-gaap | OperatingLeasePayments | Operating Lease, Payments | USD | 800,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | OperatingLeaseRightOfUseAsset | Operating Lease, Right-of-Use Asset | USD | 952,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDue | Operating Leases, Future Minimum Payments Due | USD | 1.61M | 2018-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001564590-19-006772 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueCurrent | Operating Leases, Future Minimum Payments Due, Next Twelve Months | USD | 569,000 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001564590-19-006772 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInFiveYears | Operating Leases, Future Minimum Payments, Due in Five Years | USD | 0 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001564590-19-006772 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInFourYears | Operating Leases, Future Minimum Payments, Due in Four Years | USD | 59,000 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001564590-19-006772 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInThreeYears | Operating Leases, Future Minimum Payments, Due in Three Years | USD | 395,000 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001564590-19-006772 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInTwoYears | Operating Leases, Future Minimum Payments, Due in Two Years | USD | 588,000 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001564590-19-006772 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueThereafter | Operating Leases, Future Minimum Payments, Due Thereafter | USD | 0 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001564590-19-006772 | |
| us-gaap | OperatingLeasesRentExpenseNet | Operating Leases, Rent Expense, Net | USD | 800,000 | 2018-01-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001564590-19-006772 |
| us-gaap | OperatingLeaseWeightedAverageDiscountRatePercent | Operating Lease, Weighted Average Discount Rate, Percent | pure | 0.14 | 2023-12-31 | 2023 | FY | 10-K | 2024-02-27 | 0000950170-24-021253 | |
| us-gaap | OtherAccruedLiabilitiesCurrent | Other Accrued Liabilities, Current | USD | 1.96M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | OtherAssetsCurrent | Other Assets, Current | USD | 3.51M | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-05 | 0000950170-24-121439 | |
| us-gaap | OtherAssetsNoncurrent | Other Assets, Noncurrent | USD | 0 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-03 | 0000950170-25-030394 | |
| us-gaap | OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent | USD | -143.59M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax | USD | -2.12M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | OtherLiabilitiesNoncurrent | Other Liabilities, Noncurrent | USD | 1,000 | 2020-12-31 | 2021 | FY | 10-K | 2022-03-01 | 0001564590-22-008112 | |
| us-gaap | OtherNoncashIncomeExpense | Other Noncash Income (Expense) | USD | 0 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-02-27 | 0000950170-24-021253 |
| us-gaap | OtherNonoperatingExpense | Other Nonoperating Expense | USD | 807,000 | 2025-01-01 | 2025-06-30 | 2025 | Q2 | 10-Q | 2025-08-04 | 0000950170-25-101985 |
| us-gaap | OtherNonoperatingIncomeExpense | Other Nonoperating Income (Expense) | USD | -777,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | OtherPrepaidExpenseCurrent | Other Prepaid Expense, Current | USD | 2.95M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | OtherReceivables | Other Receivables | USD | 697,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | OtherReceivablesGrossCurrent | Other Receivables, Gross, Current | USD | 2.70M | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-08-04 | 0001193125-26-332750 | |
| us-gaap | OtherReceivablesNetCurrent | Other Receivables, Net, Current | USD | 3.70M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | PaidInKindInterest | Paid-in-Kind Interest | USD | 0 | 2023-01-01 | 2023-09-30 | 2023 | Q3 | 10-Q | 2023-11-02 | 0000950170-23-058165 |
| us-gaap | PaymentOfFinancingAndStockIssuanceCosts | Payment of Financing and Stock Issuance Costs | USD | 302,000 | 2015-01-01 | 2015-09-30 | 2016 | Q3 | 10-Q | 2016-11-14 | 0001193125-16-767345 |
| us-gaap | PaymentsForProceedsFromDepositOnLoan | Payments for (Proceeds from) Deposit on Loan | USD | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-03 | 0000950170-25-030394 |
| us-gaap | PaymentsOfDebtIssuanceCosts | Payments of Debt Issuance Costs | USD | 6.17M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | PaymentsToAcquireAssetsInvestingActivities | Payments to Acquire Assets, Investing Activities | USD | 40,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | PaymentsToAcquirePropertyPlantAndEquipment | Payments to Acquire Property, Plant, and Equipment | USD | 187,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | PaymentsToAcquireShortTermInvestments | Payments to Acquire Short-term Investments | USD | 363.89M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | PreferredStockParOrStatedValuePerShare | Preferred Stock, Par or Stated Value Per Share | USD/shares | 0.001 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-04-30 | 0001193125-26-197154 | |
| us-gaap | PreferredStockSharesAuthorized | Preferred Stock, Shares Authorized | shares | 10.00M | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-04-30 | 0001193125-26-197154 | |
| us-gaap | PreferredStockSharesOutstanding | Preferred Stock, Shares Outstanding | shares | 0 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-04-30 | 0001193125-26-197154 | |
| us-gaap | PreferredStockValue | Preferred Stock, Value, Issued | USD | 0 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-04-30 | 0001193125-26-197154 | |
| us-gaap | PrepaidExpenseAndOtherAssetsCurrent | Prepaid Expense and Other Assets, Current | USD | 14.09M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | PrepaidInsurance | Prepaid Insurance | USD | 1.57M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | PrepaidRent | Prepaid Rent | USD | 56,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | ProceedsFromConvertibleDebt | Proceeds from Convertible Debt | USD | 250.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | ProceedsFromDebtNetOfIssuanceCosts | Proceeds from Debt, Net of Issuance Costs | USD | 0 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-02-28 | 0000950170-23-005079 |
| us-gaap | ProceedsFromIssuanceInitialPublicOffering | Proceeds from Issuance Initial Public Offering | USD | 52.15M | 2016-01-01 | 2016-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001564590-19-006772 |
| us-gaap | ProceedsFromIssuanceOfCommonStock | Proceeds from Issuance of Common Stock | USD | 81.20M | 2021-12-01 | 2021-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | ProceedsFromIssuanceOfConvertiblePreferredStock | Proceeds from Issuance of Convertible Preferred Stock | USD | 87.32M | 2015-01-01 | 2015-12-31 | 2017 | FY | 10-K | 2018-03-08 | 0001564590-18-004911 |
| us-gaap | ProceedsFromIssuanceOfDebt | Proceeds from Issuance of Debt | USD | 14.00M | 2014-01-01 | 2014-12-31 | 2016 | FY | 10-K | 2017-03-14 | 0001193125-17-081863 |
| us-gaap | ProceedsFromLicenseFeesReceived | Proceeds from License Fees Received | USD | 0 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-02-27 | 0000950170-24-021253 |
| us-gaap | ProceedsFromPaymentsForOtherFinancingActivities | Proceeds from (Payments for) Other Financing Activities | USD | 0 | 2021-01-01 | 2021-12-31 | 2022 | FY | 10-K | 2023-02-28 | 0000950170-23-005079 |
| us-gaap | ProceedsFromRepaymentsOfDebt | Proceeds from (Repayments of) Debt | USD | -750,000 | 2015-01-01 | 2015-09-30 | 2016 | Q3 | 10-Q | 2016-11-14 | 0001193125-16-767345 |
| us-gaap | ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale | USD | 208.93M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | ProceedsFromSaleOfMachineryAndEquipment | Proceeds from Sale of Machinery and Equipment | USD | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-03 | 0000950170-25-030394 |
| us-gaap | ProceedsFromStockOptionsExercised | Proceeds from Stock Options Exercised | USD | 19.42M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | ProceedsFromStockPlans | Proceeds from Stock Plans | USD | 625,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | ProfitLoss | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | USD | -141.47M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | PropertyPlantAndEquipmentGross | Property, Plant and Equipment, Gross | USD | 646,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | PropertyPlantAndEquipmentNet | Property, Plant and Equipment, Net | USD | 206,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | ProvisionForOtherCreditLosses | Provision for Other Credit Losses | USD | 3.67M | 2025-01-01 | 2025-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | RepaymentsOfLongTermCapitalLeaseObligations | Repayments of Long-term Capital Lease Obligations | USD | 1,000 | 2016-01-01 | 2016-03-31 | 2016 | Q1 | 10-Q | 2016-05-16 | 0001193125-16-591861 |
| us-gaap | RepaymentsOfLongTermDebt | Repayments of Long-term Debt | USD | 9.00M | 2015-01-01 | 2015-12-31 | 2017 | FY | 10-K | 2018-03-08 | 0001564590-18-004911 |
| us-gaap | ResearchAndDevelopmentExpense | Research and Development Expense | USD | 194.36M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | RestrictedCash | Restricted Cash | USD | 0 | 2022-12-31 | 2022 | FY | 10-K | 2023-02-28 | 0000950170-23-005079 | |
| us-gaap | RestrictedCashAndCashEquivalents | Restricted Cash and Cash Equivalents | USD | 216,000 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001564590-19-006772 | |
| us-gaap | RestrictedCashAndCashEquivalentsAtCarryingValue | Restricted Cash and Cash Equivalents, Current | USD | 115,000 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-05 | 0001564590-20-051287 | |
| us-gaap | RestrictedCashCurrent | Restricted Cash, Current | USD | 102,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 | |
| us-gaap | RestrictedCashNoncurrent | Restricted Cash, Noncurrent | USD | 102,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | RetainedEarningsAccumulatedDeficit | Retained Earnings (Accumulated Deficit) | USD | -1.65B | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | RevenueFromContractWithCustomerExcludingAssessedTax | Revenue from Contract with Customer, Excluding Assessed Tax | USD | 220.95M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | RoyaltyExpense | Royalty Expense | USD | 35.78M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | SalesRevenueNet | Revenue, Net (Deprecated 2018-01-31) | USD | 379,000 | 2018-01-01 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-09 | 0001564590-18-012378 |
| us-gaap | SellingGeneralAndAdministrativeExpense | Selling, General and Administrative Expense | USD | 179.68M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | ShareBasedCompensation | Share-based Payment Arrangement, Noncash Expense | USD | 41.35M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | pure | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | pure | 0.68 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | pure | 0.041 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | USD | 30.17M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | shares | 7.53M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | USD/shares | 14.32 | 2023-12-31 | 2023 | FY | 10-K | 2024-02-27 | 0000950170-24-021253 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | USD | 6.80M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period | shares | 1.40M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price | USD/shares | 19.62 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period | shares | 7,778 | 2022-01-01 | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-03 | 0000950170-22-021848 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares | 3.98M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | USD/shares | 8.74 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | USD | 56.88M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | shares | 13.13M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | USD/shares | 17.74 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value | USD | 55.09M | 2023-12-31 | 2023 | FY | 10-K | 2024-02-27 | 0000950170-24-021253 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | shares | 10.68M | 2023-12-31 | 2023 | FY | 10-K | 2024-02-27 | 0000950170-24-021253 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | USD/shares | 17.78 | 2023-12-31 | 2023 | FY | 10-K | 2024-02-27 | 0000950170-24-021253 | |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | USD/shares | 10.67 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price | USD/shares | 9.85 | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-05 | 0001564590-20-009016 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | USD/shares | 13.64 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | SharesIssued | Shares, Issued | shares | 84.81M | 2023-12-19 | 8-K | 2023-12-20 | 0000950170-23-071749 | |||
| us-gaap | SharesIssuedPricePerShare | Shares Issued, Price Per Share | USD/shares | 8 | 2020-01-31 | 2022 | Q3 | 10-Q | 2022-11-03 | 0000950170-22-021848 | |
| us-gaap | SharesOutstanding | Shares, Outstanding | shares | 84.81M | 2023-12-19 | 8-K | 2023-12-20 | 0000950170-23-071749 | |||
| us-gaap | ShortTermInvestments | Short-term Investments | USD | 291.16M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | StockholdersEquity | Stockholders' Equity Attributable to Parent | USD | -17.18M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 | |
| us-gaap | StockholdersEquityNoteStockSplitConversionRatio1 | Stockholders' Equity Note, Stock Split, Conversion Ratio | pure | 0.8 | 2016-02-24 | 2016 | FY | 10-K | 2017-03-14 | 0001193125-17-081863 | |
| us-gaap | StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans | Stock Issued During Period, Shares, Employee Stock Purchase Plans | shares | 0 | 2017-01-01 | 2017-09-30 | 2017 | Q3 | 10-Q | 2017-11-08 | 0001193125-17-336444 |
| us-gaap | StockIssuedDuringPeriodSharesNewIssues | Stock Issued During Period, Shares, New Issues | shares | 12.43M | 2023-12-01 | 2023-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | StockIssuedDuringPeriodSharesStockOptionsExercised | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | shares | 1.14M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | StockIssuedDuringPeriodValueConversionOfConvertibleSecurities | Stock Issued During Period, Value, Conversion of Convertible Securities | USD | 321.71M | 2016-01-01 | 2016-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001564590-19-006772 |
| us-gaap | StockIssuedDuringPeriodValueEmployeeStockPurchasePlan | Stock Issued During Period, Value, Employee Stock Purchase Plan | USD | 39,000 | 2017-01-01 | 2017-09-30 | 2017 | Q3 | 10-Q | 2017-11-08 | 0001193125-17-336444 |
| us-gaap | StockIssuedDuringPeriodValueNewIssues | Stock Issued During Period, Value, New Issues | USD | 24.85M | 2021-01-01 | 2021-12-31 | 2023 | FY | 10-K | 2024-02-27 | 0000950170-24-021253 |
| us-gaap | StockIssuedDuringPeriodValueRestrictedStockAwardGross | Stock Issued During Period, Value, Restricted Stock Award, Gross | USD | 59,000 | 2017-01-01 | 2017-12-31 | 2019 | FY | 10-K | 2020-03-05 | 0001564590-20-009016 |
| us-gaap | StockIssuedDuringPeriodValueStockOptionsExercised | Stock Issued During Period, Value, Stock Options Exercised | USD | 3.20M | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | StockRepurchasedAndRetiredDuringPeriodValue | Stock Repurchased and Retired During Period, Value | USD | 16.78M | 2018-01-01 | 2018-12-31 | 2020 | FY | 10-K | 2021-03-12 | 0001564590-21-012607 |
| us-gaap | StockRepurchasedDuringPeriodShares | Stock Repurchased During Period, Shares | shares | 16,731 | 2016-01-01 | 2016-12-31 | 2017 | FY | 10-K | 2018-03-08 | 0001564590-18-004911 |
| us-gaap | Supplies | Prepaid Supplies | USD | 58,000 | 2020-12-31 | 2021 | FY | 10-K | 2022-03-01 | 0001564590-22-008112 | |
| us-gaap | TangibleAssetImpairmentCharges | Tangible Asset Impairment Charges | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | TemporaryEquityAccretionToRedemptionValueAdjustment | Temporary Equity, Accretion to Redemption Value, Adjustment | USD | 69.72M | 2015-01-01 | 2015-12-31 | 2017 | FY | 10-K | 2018-03-08 | 0001564590-18-004911 |
| us-gaap | TemporaryEquityCarryingAmountAttributableToParent | Temporary Equity, Carrying Amount, Attributable to Parent | USD | 319.11M | 2015-12-31 | 2016 | FY | 10-K | 2017-03-14 | 0001193125-17-081863 | |
| us-gaap | TemporaryEquityDividendsAdjustment | Temporary Equity, Dividends, Adjustment | USD | 2.60M | 2016-01-01 | 2016-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001564590-19-006772 |
| us-gaap | UnamortizedDebtIssuanceExpense | Unamortized Debt Issuance Expense | USD | 87,000 | 2022-06-30 | 2022 | Q2 | 10-Q | 2022-08-08 | 0000950170-22-015523 | |
| us-gaap | UnamortizedLossReacquiredDebtNoncurrent | Unamortized Loss Reacquired Debt, Noncurrent | USD | 49,000 | 2020-03-31 | 2020 | Q1 | 10-Q | 2020-05-07 | 0001564590-20-022971 | |
| us-gaap | UndistributedEarningsOfForeignSubsidiaries | Undistributed Earnings of Foreign Subsidiaries | USD | 0 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001564590-19-006772 | |
| us-gaap | UnrecognizedTaxBenefits | Unrecognized Tax Benefits | USD | 143,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 | |
| us-gaap | UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions | Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | UnrecognizedTaxBenefitsPeriodIncreaseDecrease | Unrecognized Tax Benefits, Period Increase (Decrease) | USD | 100,000 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-02-27 | 0000950170-24-021253 |
| us-gaap | ValuationAllowanceDeferredTaxAssetChangeInAmount | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | USD | 81.10M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-26 | 0001193125-26-076536 |
| us-gaap | WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount | Warrant, Down Round Feature, (Increase) Decrease in Equity, Amount | USD | 3.91M | 2020-01-01 | 2020-12-31 | 2021 | FY | 10-K | 2022-03-01 | 0001564590-22-008112 |
| us-gaap | WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1 | WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1 | USD | 3.91M | 2020-01-01 | 2020-12-31 | 2022 | FY | 10-K | 2023-02-28 | 0000950170-23-005079 |
| us-gaap | WarrantsAndRightsOutstanding | Warrants and Rights Outstanding | USD | 2.85M | 2015-12-31 | 2016 | FY | 10-K | 2017-03-14 | 0001193125-17-081863 | |
| us-gaap | WeightedAverageNumberOfDilutedSharesOutstanding | Weighted Average Number of Shares Outstanding, Diluted | shares | 89.02M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |
| us-gaap | WeightedAverageNumberOfShareOutstandingBasicAndDiluted | Weighted Average Number of Shares Outstanding, Basic and Diluted | shares | 58.98M | 2022-01-01 | 2022-03-31 | 2022 | Q1 | 10-Q | 2022-05-09 | 0001564590-22-018873 |
| us-gaap | WeightedAverageNumberOfSharesOutstandingBasic | Weighted Average Number of Shares Outstanding, Basic | shares | 89.02M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-02 | 0001193125-26-443625 |